#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	D1-Dopamine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
1-2	12-20	Receptor	_
1-3	21-33	Availability	_
1-4	34-36	in	_
1-5	37-50	First-Episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-6	51-62	Neuroleptic	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-7	63-68	Naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-8	69-78	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-9	79-87	Patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-10	88-96	Abstract	_
1-11	97-107	Background	_
1-12	108-116	Positron	_
1-13	117-125	emission	_
1-14	126-136	tomography	_
1-15	137-144	studies	_
1-16	145-154	examining	_
1-17	155-166	differences	_
1-18	167-169	in	_
1-19	170-181	D1-dopamine	_
1-20	182-190	receptor	_
1-21	191-198	binding	_
1-22	199-206	between	_
1-23	207-214	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-24	215-223	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-25	224-227	and	_
1-26	228-236	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	237-241	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-28	242-255	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-29	256-260	have	_
1-30	261-265	been	_
1-31	266-278	inconsistent	_
1-32	279-280	,	_
1-33	281-290	reporting	_
1-34	291-297	higher	_
1-35	298-299	,	_
1-36	300-305	lower	_
1-37	306-307	,	_
1-38	308-311	and	_
1-39	312-314	no	_
1-40	315-325	difference	_
1-41	326-328	in	_
1-42	329-332	the	_
1-43	333-340	frontal	_
1-44	341-347	cortex	_
1-45	348-349	.	_

2-1	350-358	Exposure	_
2-2	359-361	to	_
2-3	362-375	antipsychotic	_
2-4	376-386	medication	_
2-5	387-390	has	_
2-6	391-395	been	_
2-7	396-405	suggested	_
2-8	406-408	to	_
2-9	409-411	be	_
2-10	412-413	a	_
2-11	414-420	likely	_
2-12	421-427	source	_
2-13	428-430	of	_
2-14	431-435	this	_
2-15	436-449	heterogeneity	_
2-16	450-451	,	_
2-17	452-455	and	_
2-18	456-460	thus	_
2-19	461-466	there	_
2-20	467-469	is	_
2-21	470-471	a	_
2-22	472-476	need	_
2-23	477-480	for	_
2-24	481-488	studies	_
2-25	489-491	of	_
2-26	492-500	patients	_
2-27	501-503	at	_
2-28	504-509	early	_
2-29	510-516	stages	_
2-30	517-519	of	_
2-31	520-523	the	_
2-32	524-532	disorder	_
2-33	533-536	who	_
2-34	537-541	have	_
2-35	542-545	not	_
2-36	546-550	been	_
2-37	551-558	exposed	_
2-38	559-561	to	_
2-39	562-566	such	_
2-40	567-572	drugs	_
2-41	573-574	.	_

3-1	575-582	Methods	_
3-2	583-587	Here	_
3-3	588-589	,	_
3-4	590-592	we	_
3-5	593-601	compared	_
3-6	602-604	17	_
3-7	605-612	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-8	613-620	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-9	621-629	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-10	630-633	and	_
3-11	634-636	18	_
3-12	637-650	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-13	651-662	neuroleptic	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-14	663-668	naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-15	669-677	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-16	678-682	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-17	683-696	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-18	697-699	or	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-19	700-716	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-20	717-726	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-21	727-732	using	_
3-22	733-741	positron	_
3-23	742-750	emission	_
3-24	751-761	tomography	_
3-25	762-765	and	_
3-26	766-769	the	_
3-27	770-781	D1-dopamine	_
3-28	782-790	receptor	_
3-29	791-802	radioligand	_
3-30	803-804	[	_
3-31	805-808	11C	_
3-32	809-810	]	_
3-33	811-819	SCH23390	_
3-34	820-821	.	_

4-1	822-829	Results	_
4-2	830-832	We	_
4-3	833-841	observed	_
4-4	842-843	a	_
4-5	844-857	statistically	_
4-6	858-869	significant	_
4-7	870-880	difference	_
4-8	881-883	in	_
4-9	884-887	the	_
4-10	888-900	dorsolateral	_
4-11	901-911	prefrontal	_
4-12	912-918	cortex	_
4-13	919-920	.	_

5-1	921-929	Contrary	_
5-2	930-932	to	_
5-3	933-936	our	_
5-4	937-949	expectations	_
5-5	950-951	,	_
5-6	952-960	patients	_
5-7	961-964	had	_
5-8	965-969	less	_
5-9	970-981	D1-dopamine	_
5-10	982-990	receptor	_
5-11	991-1003	availability	_
5-12	1004-1008	with	_
5-13	1009-1010	a	_
5-14	1011-1019	moderate	_
5-15	1020-1026	effect	_
5-16	1027-1031	size	_
5-17	1032-1033	.	_

6-1	1034-1036	In	_
6-2	1037-1038	a	_
6-3	1039-1047	Bayesian	_
6-4	1048-1056	analysis	_
6-5	1057-1058	,	_
6-6	1059-1061	we	_
6-7	1062-1066	show	_
6-8	1067-1071	that	_
6-9	1072-1075	the	_
6-10	1076-1080	data	_
6-11	1081-1084	are	_
6-12	1085-1089	over	_
6-13	1090-1092	50	_
6-14	1093-1098	times	_
6-15	1099-1103	more	_
6-16	1104-1110	likely	_
6-17	1111-1113	to	_
6-18	1114-1118	have	_
6-19	1119-1127	occurred	_
6-20	1128-1133	under	_
6-21	1134-1137	the	_
6-22	1138-1146	decrease	_
6-23	1147-1149	as	_
6-24	1150-1157	opposed	_
6-25	1158-1160	to	_
6-26	1161-1164	the	_
6-27	1165-1173	increase	_
6-28	1174-1184	hypothesis	_
6-29	1185-1186	.	_

7-1	1187-1191	This	_
7-2	1192-1198	effect	_
7-3	1199-1202	was	_
7-4	1203-1206	not	_
7-5	1207-1213	global	_
7-6	1214-1215	,	_
7-7	1216-1218	as	_
7-8	1219-1222	our	_
7-9	1223-1231	analysis	_
7-10	1232-1238	showed	_
7-11	1239-1243	that	_
7-12	1244-1247	the	_
7-13	1248-1252	null	_
7-14	1253-1263	hypothesis	_
7-15	1264-1267	was	_
7-16	1268-1277	preferred	_
7-17	1278-1282	over	_
7-18	1283-1289	either	_
7-19	1290-1300	hypothesis	_
7-20	1301-1303	in	_
7-21	1304-1307	the	_
7-22	1308-1316	striatum	_
7-23	1317-1318	.	_

8-1	1319-1330	Conclusions	_
8-2	1331-1335	This	_
8-3	1336-1349	investigation	_
8-4	1350-1360	represents	_
8-5	1361-1364	the	_
8-6	1365-1372	largest	_
8-7	1373-1379	single	_
8-8	1380-1386	sample	_
8-9	1387-1389	of	_
8-10	1390-1407	neuroleptic-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
8-11	1408-1416	patients	_
8-12	1417-1425	examined	_
8-13	1426-1429	for	_
8-14	1430-1441	D1-dopamine	_
8-15	1442-1450	receptor	_
8-16	1451-1463	availability	_
8-17	1464-1469	using	_
8-18	1470-1473	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
8-19	1474-1477	and	_
8-20	1478-1486	suggests	_
8-21	1487-1488	a	_
8-22	1489-1498	reduction	_
8-23	1499-1501	of	_
8-24	1502-1512	prefrontal	_
8-25	1513-1524	D1-dopamine	_
8-26	1525-1533	receptor	_
8-27	1534-1541	density	_
8-28	1542-1544	in	_
8-29	1545-1548	the	_
8-30	1549-1564	pathophysiology	_
8-31	1565-1567	of	_
8-32	1568-1581	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-33	1582-1583	.	_

9-1	1584-1591	However	_
9-2	1592-1593	,	_
9-3	1594-1601	further	_
9-4	1602-1606	work	_
9-5	1607-1611	will	_
9-6	1612-1614	be	_
9-7	1615-1623	required	_
9-8	1624-1626	to	_
9-9	1627-1632	reach	_
9-10	1633-1634	a	_
9-11	1635-1644	consensus	_
9-12	1645-1646	.	_

10-1	1647-1656	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1657-1660	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1661-1668	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1669-1677	Subjects	_
10-5	1678-1681	The	_
10-6	1682-1687	study	_
10-7	1688-1691	was	_
10-8	1692-1701	conducted	_
10-9	1702-1704	in	_
10-10	1705-1715	compliance	_
10-11	1716-1720	with	_
10-12	1721-1724	the	_
10-13	1725-1732	ethical	_
10-14	1733-1743	principles	_
10-15	1744-1755	originating	_
10-16	1756-1758	in	_
10-17	1759-1762	the	_
10-18	1763-1774	Declaration	_
10-19	1775-1777	of	_
10-20	1778-1786	Helsinki	_
10-21	1787-1790	and	_
10-22	1791-1794	the	_
10-23	1795-1799	Good	_
10-24	1800-1808	Clinical	_
10-25	1809-1817	Practice	_
10-26	1818-1828	Guidelines	_
10-27	1829-1831	of	_
10-28	1832-1835	the	_
10-29	1836-1849	International	_
10-30	1850-1860	Conference	_
10-31	1861-1863	on	_
10-32	1864-1877	Harmonization	_
10-33	1878-1879	.	_

11-1	1880-1883	The	_
11-2	1884-1889	study	_
11-3	1890-1893	was	_
11-4	1894-1902	approved	_
11-5	1903-1905	by	_
11-6	1906-1909	the	_
11-7	1910-1916	Ethics	_
11-8	1917-1926	Committee	_
11-9	1927-1930	and	_
11-10	1931-1934	the	_
11-11	1935-1944	Radiation	_
11-12	1945-1951	Safety	_
11-13	1952-1961	Committee	_
11-14	1962-1964	at	_
11-15	1965-1968	the	_
11-16	1969-1979	Karolinska	_
11-17	1980-1990	University	_
11-18	1991-1999	Hospital	_
11-19	2000-2001	(	_
11-20	2002-2011	Stockholm	_
11-21	2012-2013	,	_
11-22	2014-2020	Sweden	_
11-23	2021-2022	)	_
11-24	2023-2024	.	_

12-1	2025-2033	Eighteen	_
12-2	2034-2042	patients	_
12-3	2043-2044	,	_
12-4	2045-2049	aged	_
12-5	2050-2052	19	_
12-6	2053-2055	to	_
12-7	2056-2058	51	_
12-8	2059-2064	years	_
12-9	2065-2066	,	_
12-10	2067-2070	and	_
12-11	2071-2073	18	_
12-12	2074-2081	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-13	2082-2089	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-14	2090-2098	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-15	2099-2100	,	_
12-16	2101-2105	aged	_
12-17	2106-2108	22	_
12-18	2109-2111	to	_
12-19	2112-2114	52	_
12-20	2115-2120	years	_
12-21	2121-2122	,	_
12-22	2123-2127	were	_
12-23	2128-2136	enrolled	_
12-24	2137-2142	after	_
12-25	2143-2150	written	_
12-26	2151-2159	informed	_
12-27	2160-2167	consent	_
12-28	2168-2170	at	_
12-29	2171-2174	the	_
12-30	2175-2181	Center	_
12-31	2182-2185	for	_
12-32	2186-2196	Psychiatry	_
12-33	2197-2205	Research	_
12-34	2206-2207	,	_
12-35	2208-2218	Department	_
12-36	2219-2221	of	_
12-37	2222-2230	Clinical	_
12-38	2231-2243	Neuroscience	_
12-39	2244-2245	,	_
12-40	2246-2256	Karolinska	_
12-41	2257-2267	Institutet	_
12-42	2268-2269	,	_
12-43	2270-2273	and	_
12-44	2274-2283	Stockholm	_
12-45	2284-2290	County	_
12-46	2291-2298	Council	_
12-47	2299-2300	,	_
12-48	2301-2310	Stockholm	_
12-49	2311-2312	,	_
12-50	2313-2319	Sweden	_
12-51	2320-2321	.	_

13-1	2322-2326	None	_
13-2	2327-2329	of	_
13-3	2330-2335	these	_
13-4	2336-2344	patients	_
13-5	2345-2349	were	_
13-6	2350-2358	included	_
13-7	2359-2361	in	_
13-8	2362-2365	our	_
13-9	2366-2374	previous	_
13-10	2375-2380	study	_
13-11	2381-2383	of	_
13-12	2384-2387	D1R	_
13-13	2388-2390	in	_
13-14	2391-2404	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-15	2405-2414	psychosis	_
13-16	2415-2416	.	_

14-1	2417-2426	Exclusion	_
14-2	2427-2435	criteria	_
14-3	2436-2439	for	_
14-4	2440-2443	the	_
14-5	2444-2451	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-6	2452-2462	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-7	2463-2466	and	_
14-8	2467-2470	the	_
14-9	2471-2479	patients	_
14-10	2480-2484	were	_
14-11	2485-2499	nonpsychiatric	_
14-12	2500-2505	brain	_
14-13	2506-2514	disorder	_
14-14	2515-2516	,	_
14-15	2517-2522	other	_
14-16	2523-2530	somatic	_
14-17	2531-2539	disorder	_
14-18	2540-2541	,	_
14-19	2542-2549	history	_
14-20	2550-2552	of	_
14-21	2553-2557	head	_
14-22	2558-2564	injury	_
14-23	2565-2569	with	_
14-24	2570-2574	loss	_
14-25	2575-2577	of	_
14-26	2578-2591	consciousness	_
14-27	2592-2595	for	_
14-28	2596-2600	more	_
14-29	2601-2605	than	_
14-30	2606-2607	5	_
14-31	2608-2615	minutes	_
14-32	2616-2617	,	_
14-33	2618-2625	cranial	_
14-34	2626-2634	fracture	_
14-35	2635-2636	,	_
14-36	2637-2644	history	_
14-37	2645-2647	or	_
14-38	2648-2656	presence	_
14-39	2657-2659	of	_
14-40	2660-2668	epilepsy	_
14-41	2669-2670	,	_
14-42	2671-2679	previous	_
14-43	2680-2689	treatment	_
14-44	2690-2694	with	_
14-45	2695-2708	antipsychotic	_
14-46	2709-2714	drugs	_
14-47	2715-2716	,	_
14-48	2717-2727	clinically	_
14-49	2728-2739	significant	_
14-50	2740-2748	abnormal	_
14-51	2749-2759	laboratory	_
14-52	2760-2764	test	_
14-53	2765-2772	results	_
14-54	2773-2774	,	_
14-55	2775-2784	pregnancy	_
14-56	2785-2786	,	_
14-57	2787-2790	and	_
14-58	2791-2798	history	_
14-59	2799-2801	of	_
14-60	2802-2809	alcohol	_
14-61	2810-2812	or	_
14-62	2813-2817	drug	_
14-63	2818-2823	abuse	_
14-64	2824-2833	according	_
14-65	2834-2836	to	_
14-66	2837-2846	DSM-III-R	_
14-67	2847-2855	criteria	_
14-68	2856-2858	or	_
14-69	2859-2867	frequent	_
14-70	2868-2876	nicotine	_
14-71	2877-2880	use	_
14-72	2881-2884	and	_
14-73	2885-2890	brain	_
14-74	2891-2897	injury	_
14-75	2898-2899	.	_

15-1	2900-2907	Further	_
15-2	2908-2917	exclusion	_
15-3	2918-2926	criteria	_
15-4	2927-2930	for	_
15-5	2931-2934	the	_
15-6	2935-2942	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-7	2943-2953	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-8	2954-2958	were	_
15-9	2959-2966	history	_
15-10	2967-2969	or	_
15-11	2970-2978	presence	_
15-12	2979-2981	of	_
15-13	2982-2985	any	_
15-14	2986-2997	psychiatric	_
15-15	2998-3006	disorder	_
15-16	3007-3010	and	_
15-17	3011-3018	history	_
15-18	3019-3021	of	_
15-19	3022-3023	a	_
15-20	3024-3035	psychiatric	_
15-21	3036-3044	disorder	_
15-22	3045-3047	in	_
15-23	3048-3049	a	_
15-24	3050-3062	first-degree	_
15-25	3063-3071	relative	_
15-26	3072-3073	.	_

16-1	3074-3077	All	_
16-2	3078-3086	patients	_
16-3	3087-3091	were	_
16-4	3092-3101	recruited	_
16-5	3102-3104	by	_
16-6	3105-3108	P.S	_
16-7	3109-3110	.	_

17-1	3111-3115	from	_
17-2	3116-3119	the	_
17-3	3120-3130	psychiatry	_
17-4	3131-3137	clinic	_
17-5	3138-3140	at	_
17-6	3141-3144	the	_
17-7	3145-3155	Karolinska	_
17-8	3156-3166	University	_
17-9	3167-3175	Hospital	_
17-10	3176-3177	,	_
17-11	3178-3186	admitted	_
17-12	3187-3190	for	_
17-13	3191-3194	the	_
17-14	3195-3200	first	_
17-15	3201-3205	time	_
17-16	3206-3208	to	_
17-17	3209-3220	psychiatric	_
17-18	3221-3229	services	_
17-19	3230-3231	,	_
17-20	3232-3235	and	_
17-21	3236-3245	diagnosed	_
17-22	3246-3250	with	_
17-23	3251-3264	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
17-24	3265-3267	or	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
17-25	3268-3284	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
17-26	3285-3294	psychosis	_
17-27	3295-3304	according	_
17-28	3305-3307	to	_
17-29	3308-3317	DSM-III-R	_
17-30	3318-3319	(	_
17-31	3320-3325	Table	_
17-32	3326-3327	1	_
17-33	3328-3329	)	_
17-34	3330-3331	.	_

18-1	3332-3335	The	_
18-2	3336-3347	recruitment	_
18-3	3348-3353	phase	_
18-4	3354-3360	lasted	_
18-5	3361-3365	from	_
18-6	3366-3370	1994	_
18-7	3371-3373	to	_
18-8	3374-3378	2007	_
18-9	3379-3380	.	_

19-1	3381-3383	In	_
19-2	3384-3392	addition	_
19-3	3393-3394	,	_
19-4	3395-3399	each	_
19-5	3400-3407	patient	_
19-6	3408-3411	was	_
19-7	3412-3420	followed	_
19-8	3421-3434	prospectively	_
19-9	3435-3444	regarding	_
19-10	3445-3454	diagnosis	_
19-11	3455-3458	for	_
19-12	3459-3460	1	_
19-13	3461-3465	year	_
19-14	3466-3471	after	_
19-15	3472-3481	inclusion	_
19-16	3482-3484	in	_
19-17	3485-3488	the	_
19-18	3489-3494	study	_
19-19	3495-3496	.	_

20-1	3497-3505	Clinical	_
20-2	3506-3513	Ratings	_
20-3	3514-3522	Patients	_
20-4	3523-3524	’	_
20-5	3525-3533	clinical	_
20-6	3534-3542	symptoms	_
20-7	3543-3547	were	_
20-8	3548-3553	rated	_
20-9	3554-3556	by	_
20-10	3557-3562	using	_
20-11	3563-3566	the	_
20-12	3567-3574	18-item	_
20-13	3575-3580	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-14	3581-3592	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-15	3593-3599	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-16	3600-3605	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-17	3606-3607	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-18	3608-3612	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-19	3613-3614	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-20	3615-3616	(	_
20-21	3617-3621	each	_
20-22	3622-3626	item	_
20-23	3627-3632	rated	_
20-24	3633-3635	on	_
20-25	3636-3637	a	_
20-26	3638-3641	0–6	_
20-27	3642-3647	scale	_
20-28	3648-3649	)	_
20-29	3650-3651	.	_

21-1	3652-3655	The	_
21-2	3656-3663	overall	_
21-3	3664-3669	total	_
21-4	3670-3676	rating	_
21-5	3677-3680	and	_
21-6	3681-3687	scores	_
21-7	3688-3690	on	_
21-8	3691-3699	positive	_
21-9	3700-3703	and	_
21-10	3704-3712	negative	_
21-11	3713-3720	symptom	_
21-12	3721-3729	clusters	_
21-13	3730-3734	were	_
21-14	3735-3739	used	_
21-15	3740-3741	.	_

22-1	3742-3745	The	_
22-2	3746-3754	positive	_
22-3	3755-3762	symptom	_
22-4	3763-3770	cluster	_
22-5	3771-3779	consists	_
22-6	3780-3782	of	_
22-7	3783-3793	conceptual	_
22-8	3794-3809	disorganization	_
22-9	3810-3811	,	_
22-10	3812-3826	suspiciousness	_
22-11	3827-3828	,	_
22-12	3829-3842	hallucinatory	_
22-13	3843-3851	behavior	_
22-14	3852-3853	,	_
22-15	3854-3857	and	_
22-16	3858-3865	unusual	_
22-17	3866-3873	thought	_
22-18	3874-3881	content	_
22-19	3882-3883	(	_
22-20	3884-3888	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
22-21	3889-3894	items	_
22-22	3895-3896	4	_
22-23	3897-3898	,	_
22-24	3899-3901	11	_
22-25	3902-3903	,	_
22-26	3904-3906	12	_
22-27	3907-3908	,	_
22-28	3909-3912	and	_
22-29	3913-3915	15	_
22-30	3916-3917	)	_
22-31	3918-3919	.	_

23-1	3920-3923	The	_
23-2	3924-3932	negative	_
23-3	3933-3940	symptom	_
23-4	3941-3948	cluster	_
23-5	3949-3957	consists	_
23-6	3958-3960	of	_
23-7	3961-3970	emotional	_
23-8	3971-3981	withdrawal	_
23-9	3982-3983	,	_
23-10	3984-3989	motor	_
23-11	3990-4001	retardation	_
23-12	4002-4003	,	_
23-13	4004-4007	and	_
23-14	4008-4015	blunted	_
23-15	4016-4022	affect	_
23-16	4023-4024	(	_
23-17	4025-4029	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
23-18	4030-4035	items	_
23-19	4036-4037	3	_
23-20	4038-4039	,	_
23-21	4040-4042	13	_
23-22	4043-4046	and	_
23-23	4047-4049	16	_
23-24	4050-4051	)	_
23-25	4052-4053	.	_

24-1	4054-4061	General	_
24-2	4062-4070	Comments	_
24-3	4071-4073	on	_
24-4	4074-4077	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-5	4078-4081	and	_
24-6	4082-4085	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
24-7	4086-4093	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
24-8	4094-4097	Due	_
24-9	4098-4100	to	_
24-10	4101-4104	the	_
24-11	4105-4107	14	_
24-12	4108-4113	years	_
24-13	4114-4121	between	_
24-14	4122-4133	examination	_
24-15	4134-4136	of	_
24-16	4137-4140	the	_
24-17	4141-4146	first	_
24-18	4147-4150	and	_
24-19	4151-4154	the	_
24-20	4155-4159	last	_
24-21	4160-4167	subject	_
24-22	4168-4169	,	_
24-23	4170-4175	there	_
24-24	4176-4180	were	_
24-25	4181-4190	technical	_
24-26	4191-4198	changes	_
24-27	4199-4204	along	_
24-28	4205-4208	the	_
24-29	4209-4212	way	_
24-30	4213-4215	in	_
24-31	4216-4220	some	_
24-32	4221-4223	of	_
24-33	4224-4227	the	_
24-34	4228-4240	experimental	_
24-35	4241-4251	procedures	_
24-36	4252-4253	.	_

25-1	4254-4257	The	_
25-2	4258-4265	changes	_
25-3	4266-4275	comprised	_
25-4	4276-4279	the	_
25-5	4280-4283	use	_
25-6	4284-4286	of	_
25-7	4287-4296	different	_
25-8	4297-4300	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-9	4301-4310	protocols	_
25-10	4311-4312	,	_
25-11	4313-4316	the	_
25-12	4317-4320	use	_
25-13	4321-4323	of	_
25-14	4324-4335	Neuroinsert	_
25-15	4336-4337	(	_
25-16	4338-4339	a	_
25-17	4340-4343	PET	_
25-18	4344-4350	gantry	_
25-19	4351-4357	device	_
25-20	4358-4360	in	_
25-21	4361-4365	lead	_
25-22	4366-4375	shielding	_
25-23	4376-4385	radiation	_
25-24	4386-4397	originating	_
25-25	4398-4402	from	_
25-26	4403-4406	the	_
25-27	4407-4412	trunk	_
25-28	4413-4414	)	_
25-29	4415-4416	,	_
25-30	4417-4420	the	_
25-31	4421-4424	PET	_
25-32	4425-4436	acquisition	_
25-33	4437-4441	time	_
25-34	4442-4448	length	_
25-35	4449-4450	,	_
25-36	4451-4465	reconstruction	_
25-37	4466-4476	parameters	_
25-38	4477-4478	,	_
25-39	4479-4482	and	_
25-40	4483-4487	file	_
25-41	4488-4495	formats	_
25-42	4496-4497	.	_

26-1	4498-4501	The	_
26-2	4502-4514	experimental	_
26-3	4515-4525	procedures	_
26-4	4526-4529	and	_
26-5	4530-4538	settings	_
26-6	4539-4542	are	_
26-7	4543-4546	for	_
26-8	4547-4551	each	_
26-9	4552-4562	individual	_
26-10	4563-4569	listed	_
26-11	4570-4572	in	_
26-12	4573-4586	Supplementary	_
26-13	4587-4596	Materials	_
26-14	4597-4598	2	_
26-15	4599-4600	.	_

27-1	4601-4603	As	_
27-2	4604-4613	described	_
27-3	4614-4619	below	_
27-4	4620-4621	,	_
27-5	4622-4625	the	_
27-6	4626-4637	differences	_
27-7	4638-4640	in	_
27-8	4641-4653	experimental	_
27-9	4654-4664	procedures	_
27-10	4665-4669	were	_
27-11	4670-4671	,	_
27-12	4672-4676	when	_
27-13	4677-4679	so	_
27-14	4680-4688	required	_
27-15	4689-4690	,	_
27-16	4691-4699	included	_
27-17	4700-4702	as	_
27-18	4703-4714	confounders	_
27-19	4715-4717	in	_
27-20	4718-4721	the	_
27-21	4722-4733	statistical	_
27-22	4734-4742	analysis	_
27-23	4743-4744	.	_

28-1	4745-4748	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-2	4749-4760	Examination	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-3	4761-4764	All	_
28-4	4765-4773	subjects	_
28-5	4774-4783	underwent	_
28-6	4784-4785	a	_
28-7	4786-4797	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
28-8	4798-4801	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
28-9	4802-4813	measurement	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
28-10	4814-4816	to	_
28-11	4817-4821	rule	_
28-12	4822-4825	out	_
28-13	4826-4829	any	_
28-14	4830-4835	brain	_
28-15	4836-4847	abnormality	_
28-16	4848-4849	.	_

29-1	4850-4852	In	_
29-2	4853-4856	the	_
29-3	4857-4866	beginning	_
29-4	4867-4869	of	_
29-5	4870-4874	data	_
29-6	4875-4885	collection	_
29-7	4886-4887	,	_
29-8	4888-4892	only	_
29-9	4893-4896	the	_
29-10	4897-4899	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
29-11	4900-4908	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
29-12	4909-4912	was	_
29-13	4913-4922	performed	_
29-14	4923-4924	(	_
29-15	4925-4926	n	_
29-16	4927-4928	=	_
29-17	4929-4931	16	_
29-18	4932-4933	)	_
29-19	4934-4936	on	_
29-20	4937-4938	a	_
29-21	4939-4944	1.5-T	_
29-22	4945-4950	Signa	_
29-23	4951-4955	unit	_
29-24	4956-4957	(	_
29-25	4958-4965	General	_
29-26	4966-4974	Electric	_
29-27	4975-4976	,	_
29-28	4977-4986	Milwaukee	_
29-29	4987-4988	,	_
29-30	4989-4991	WI	_
29-31	4992-4993	)	_
29-32	4994-4995	.	_

30-1	4996-4997	A	_
30-2	4998-5006	standard	_
30-3	5007-5016	spin-echo	_
30-4	5017-5025	sequence	_
30-5	5026-5030	with	_
30-6	5031-5032	a	_
30-7	5033-5036	256	_
30-8	5037-5038	×	_
30-9	5039-5042	256	_
30-10	5043-5049	matrix	_
30-11	5050-5053	was	_
30-12	5054-5058	used	_
30-13	5059-5063	with	_
30-14	5064-5065	a	_
30-15	5066-5076	repetition	_
30-16	5077-5081	time	_
30-17	5082-5084	of	_
30-18	5085-5086	4	_
30-19	5087-5094	seconds	_
30-20	5095-5096	.	_

31-1	5097-5101	Echo	_
31-2	5102-5107	times	_
31-3	5108-5110	85	_
31-4	5111-5115	msec	_
31-5	5116-5120	with	_
31-6	5121-5122	a	_
31-7	5123-5128	total	_
31-8	5129-5137	scanning	_
31-9	5138-5142	time	_
31-10	5143-5145	of	_
31-11	5146-5151	about	_
31-12	5152-5154	10	_
31-13	5155-5162	minutes	_
31-14	5163-5164	.	_

32-1	5165-5168	The	_
32-2	5169-5173	long	_
32-3	5174-5178	echo	_
32-4	5179-5183	time	_
32-5	5184-5187	was	_
32-6	5188-5190	to	_
32-7	5191-5198	enhance	_
32-8	5199-5202	the	_
32-9	5203-5207	grey	_
32-10	5208-5211	and	_
32-11	5212-5217	white	_
32-12	5218-5224	matter	_
32-13	5225-5237	segmentation	_
32-14	5238-5240	to	_
32-15	5241-5246	allow	_
32-16	5247-5250	the	_
32-17	5251-5262	delineation	_
32-18	5263-5265	of	_
32-19	5266-5273	regions	_
32-20	5274-5276	of	_
32-21	5277-5285	interest	_
32-22	5286-5287	(	_
32-23	5288-5292	ROIs	_
32-24	5293-5294	)	_
32-25	5295-5296	.	_

33-1	5297-5300	The	_
33-2	5301-5310	rationale	_
33-3	5311-5314	for	_
33-4	5315-5321	having	_
33-5	5322-5326	only	_
33-6	5327-5330	one	_
33-7	5331-5334	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-8	5335-5343	sequence	_
33-9	5344-5347	was	_
33-10	5348-5350	to	_
33-11	5351-5357	reduce	_
33-12	5358-5361	the	_
33-13	5362-5366	risk	_
33-14	5367-5369	of	_
33-15	5370-5383	noncompliance	_
33-16	5384-5388	with	_
33-17	5389-5390	a	_
33-18	5391-5397	longer	_
33-19	5398-5409	examination	_
33-20	5410-5419	including	_
33-21	5420-5427	several	_
33-22	5428-5437	sequences	_
33-23	5438-5439	.	_

34-1	5440-5442	In	_
34-2	5443-5451	addition	_
34-3	5452-5453	,	_
34-4	5454-5457	the	_
34-5	5458-5465	primary	_
34-6	5466-5473	purpose	_
34-7	5474-5476	of	_
34-8	5477-5480	the	_
34-9	5481-5484	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-10	5485-5488	was	_
34-11	5489-5490	a	_
34-12	5491-5499	clinical	_
34-13	5500-5511	examination	_
34-14	5512-5514	to	_
34-15	5515-5519	rule	_
34-16	5520-5523	out	_
34-17	5524-5527	any	_
34-18	5528-5537	pathology	_
34-19	5538-5539	.	_

35-1	5540-5545	Later	_
35-2	5546-5548	in	_
35-3	5549-5552	the	_
35-4	5553-5557	data	_
35-5	5558-5568	collection	_
35-6	5569-5570	,	_
35-7	5571-5579	software	_
35-8	5580-5583	and	_
35-9	5584-5588	coil	_
35-10	5589-5596	upgrade	_
35-11	5597-5601	with	_
35-12	5602-5610	improved	_
35-13	5611-5613	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
35-14	5614-5623	sequences	_
35-15	5624-5631	allowed	_
35-16	5632-5635	for	_
35-17	5636-5643	shorter	_
35-18	5644-5652	scanning	_
35-19	5653-5657	time	_
35-20	5658-5659	,	_
35-21	5660-5663	and	_
35-22	5664-5667	the	_
35-23	5668-5677	remaining	_
35-24	5678-5686	subjects	_
35-25	5687-5688	(	_
35-26	5689-5690	n	_
35-27	5691-5692	=	_
35-28	5693-5695	19	_
35-29	5696-5697	)	_
35-30	5698-5701	had	_
35-31	5702-5703	,	_
35-32	5704-5706	in	_
35-33	5707-5715	addition	_
35-34	5716-5718	to	_
35-35	5719-5722	the	_
35-36	5723-5734	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-37	5735-5743	protocol	_
35-38	5744-5745	,	_
35-39	5746-5747	a	_
35-40	5748-5759	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-41	5760-5768	sequence	_
35-42	5769-5772	for	_
35-43	5773-5781	improved	_
35-44	5782-5786	grey	_
35-45	5787-5790	and	_
35-46	5791-5796	white	_
35-47	5797-5803	matter	_
35-48	5804-5816	segmentation	_
35-49	5817-5821	with	_
35-50	5822-5823	a	_
35-51	5824-5829	total	_
35-52	5830-5838	scanning	_
35-53	5839-5843	time	_
35-54	5844-5846	of	_
35-55	5847-5852	about	_
35-56	5853-5855	10	_
35-57	5856-5863	minutes	_
35-58	5864-5865	.	_

36-1	5866-5870	This	_
36-2	5871-5873	T2	_
36-3	5874-5882	protocol	_
36-4	5883-5886	was	_
36-5	5887-5892	based	_
36-6	5893-5895	on	_
36-7	5896-5899	the	_
36-8	5900-5909	following	_
36-9	5910-5918	sequence	_
36-10	5919-5920	:	_
36-11	5921-5931	repetition	_
36-12	5932-5941	time/echo	_
36-13	5942-5946	time	_
36-14	5947-5948	=	_
36-15	5949-5958	6060/92.6	_
36-16	5959-5971	milliseconds	_
36-17	5972-5973	,	_
36-18	5974-5979	field	_
36-19	5980-5982	of	_
36-20	5983-5987	view	_
36-21	5988-5991	260	_
36-22	5992-5994	mm	_
36-23	5995-5996	,	_
36-24	5997-6002	image	_
36-25	6003-6009	matrix	_
36-26	6010-6013	256	_
36-27	6014-6015	×	_
36-28	6016-6019	256	_
36-29	6020-6021	,	_
36-30	6022-6039	thickness/spacing	_
36-31	6040-6045	3/0,1	_
36-32	6046-6048	mm	_
36-33	6049-6050	,	_
36-34	6051-6055	flip	_
36-35	6056-6061	angle	_
36-36	6062-6066	150°	_
36-37	6067-6068	,	_
36-38	6069-6074	slice	_
36-39	6075-6084	thickness	_
36-40	6085-6086	=	_
36-41	6087-6088	5	_
36-42	6089-6091	mm	_
36-43	6092-6093	.	_

37-1	6094-6097	The	_
37-2	6098-6100	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-3	6101-6109	protocol	_
37-4	6110-6113	was	_
37-5	6114-6119	based	_
37-6	6120-6122	on	_
37-7	6123-6124	a	_
37-8	6125-6138	3-dimensional	_
37-9	6139-6144	axial	_
37-10	6145-6152	Spoiled	_
37-11	6153-6161	Gradient	_
37-12	6162-6170	Recalled	_
37-13	6171-6182	Acquisition	_
37-14	6183-6187	with	_
37-15	6188-6191	the	_
37-16	6192-6201	following	_
37-17	6202-6210	sequence	_
37-18	6211-6212	:	_
37-19	6213-6223	repetition	_
37-20	6224-6233	time/echo	_
37-21	6234-6238	time	_
37-22	6239-6240	=	_
37-23	6241-6245	20/5	_
37-24	6246-6258	milliseconds	_
37-25	6259-6260	,	_
37-26	6261-6266	field	_
37-27	6267-6269	of	_
37-28	6270-6274	view	_
37-29	6275-6278	260	_
37-30	6279-6281	mm	_
37-31	6282-6283	,	_
37-32	6284-6289	image	_
37-33	6290-6296	matrix	_
37-34	6297-6300	256	_
37-35	6301-6302	×	_
37-36	6303-6306	256	_
37-37	6307-6308	,	_
37-38	6309-6326	thickness/spacing	_
37-39	6327-6330	1/0	_
37-40	6331-6333	mm	_
37-41	6334-6335	,	_
37-42	6336-6340	flip	_
37-43	6341-6346	angle	_
37-44	6347-6350	35°	_
37-45	6351-6352	.	_

38-1	6353-6356	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
38-2	6357-6368	Examination	_
38-3	6369-6372	For	_
38-4	6373-6377	each	_
38-5	6378-6385	subject	_
38-6	6386-6387	,	_
38-7	6388-6391	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
38-8	6392-6404	examinations	_
38-9	6405-6409	were	_
38-10	6410-6419	performed	_
38-11	6420-6422	on	_
38-12	6423-6426	the	_
38-13	6427-6434	Siemens	_
38-14	6435-6439	ECAT	_
38-15	6440-6445	EXACT	_
38-16	6446-6448	HR	_
38-17	6449-6452	PET	_
38-18	6453-6459	system	_
38-19	6460-6461	.	_

39-1	6462-6475	Radioactivity	_
39-2	6476-6478	in	_
39-3	6479-6484	brain	_
39-4	6485-6488	was	_
39-5	6489-6497	measured	_
39-6	6498-6502	with	_
39-7	6503-6505	2D	_
39-8	6506-6510	data	_
39-9	6511-6522	acquisition	_
39-10	6523-6524	,	_
39-11	6525-6531	except	_
39-12	6532-6535	for	_
39-13	6536-6537	2	_
39-14	6538-6546	subjects	_
39-15	6547-6550	who	_
39-16	6551-6554	had	_
39-17	6555-6557	3D	_
39-18	6558-6562	data	_
39-19	6563-6574	acquisition	_
39-20	6575-6576	.	_

40-1	6577-6580	The	_
40-2	6581-6588	spatial	_
40-3	6589-6599	resolution	_
40-4	6600-6602	in	_
40-5	6603-6606	the	_
40-6	6607-6620	reconstructed	_
40-7	6621-6629	sections	_
40-8	6630-6632	is	_
40-9	6633-6636	3.8	_
40-10	6637-6639	mm	_
40-11	6640-6642	at	_
40-12	6643-6646	the	_
40-13	6647-6653	center	_
40-14	6654-6656	of	_
40-15	6657-6660	the	_
40-16	6661-6666	field	_
40-17	6667-6669	of	_
40-18	6670-6674	view	_
40-19	6675-6676	.	_

41-1	6677-6678	A	_
41-2	6679-6691	transmission	_
41-3	6692-6696	scan	_
41-4	6697-6700	was	_
41-5	6701-6710	performed	_
41-6	6711-6716	using	_
41-7	6717-6718	3	_
41-8	6719-6727	rotating	_
41-9	6728-6732	68Ge	_
41-10	6733-6736	rod	_
41-11	6737-6744	sources	_
41-12	6745-6748	for	_
41-13	6749-6754	about	_
41-14	6755-6756	5	_
41-15	6757-6764	minutes	_
41-16	6765-6766	.	_

42-1	6767-6769	To	_
42-2	6770-6778	minimize	_
42-3	6779-6783	head	_
42-4	6784-6792	movement	_
42-5	6793-6799	during	_
42-6	6800-6803	the	_
42-7	6804-6807	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
42-8	6808-6819	measurement	_
42-9	6820-6821	,	_
42-10	6822-6823	a	_
42-11	6824-6831	plaster	_
42-12	6832-6838	helmet	_
42-13	6839-6842	was	_
42-14	6843-6847	made	_
42-15	6848-6851	for	_
42-16	6852-6856	each	_
42-17	6857-6864	subject	_
42-18	6865-6877	individually	_
42-19	6878-6881	and	_
42-20	6882-6886	used	_
42-21	6887-6893	during	_
42-22	6894-6897	the	_
42-23	6898-6901	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
42-24	6902-6913	measurement	_
42-25	6914-6915	.	_

43-1	6916-6918	At	_
43-2	6919-6922	the	_
43-3	6923-6928	start	_
43-4	6929-6931	of	_
43-5	6932-6935	the	_
43-6	6936-6939	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
43-7	6940-6951	measurement	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
43-8	6952-6953	,	_
43-9	6954-6955	a	_
43-10	6956-6963	sterile	_
43-11	6964-6973	phosphate	_
43-12	6974-6980	buffer	_
43-13	6981-6982	(	_
43-14	6983-6985	pH	_
43-15	6986-6987	=	_
43-16	6988-6991	7.4	_
43-17	6992-6993	)	_
43-18	6994-7004	containing	_
43-19	7005-7006	[	_
43-20	7007-7010	11C	_
43-21	7011-7012	]	_
43-22	7013-7021	SCH23390	_
43-23	7022-7025	was	_
43-24	7026-7034	injected	_
43-25	7035-7037	as	_
43-26	7038-7039	a	_
43-27	7040-7045	bolus	_
43-28	7046-7052	during	_
43-29	7053-7060	several	_
43-30	7061-7068	seconds	_
43-31	7069-7073	into	_
43-32	7074-7077	the	_
43-33	7078-7085	cubital	_
43-34	7086-7090	vein	_
43-35	7091-7092	.	_

44-1	7093-7096	The	_
44-2	7097-7103	venous	_
44-3	7104-7112	catheter	_
44-4	7113-7116	was	_
44-5	7117-7121	then	_
44-6	7122-7133	immediately	_
44-7	7134-7141	flushed	_
44-8	7142-7146	with	_
44-9	7147-7149	up	_
44-10	7150-7152	to	_
44-11	7153-7158	10-mL	_
44-12	7159-7165	saline	_
44-13	7166-7174	solution	_
44-14	7175-7176	.	_

45-1	7177-7178	[	_
45-2	7179-7182	11C	_
45-3	7183-7184	]	_
45-4	7185-7193	SCH23390	_
45-5	7194-7197	was	_
45-6	7198-7206	prepared	_
45-7	7207-7209	as	_
45-8	7210-7220	previously	_
45-9	7221-7230	described	_
45-10	7231-7232	.	_

46-1	7233-7236	The	_
46-2	7237-7245	injected	_
46-3	7246-7259	radioactivity	_
46-4	7260-7263	was	_
46-5	7264-7267	317	_
46-6	7268-7269	±	_
46-7	7270-7272	22	_
46-8	7273-7276	MBq	_
46-9	7277-7278	(	_
46-10	7279-7283	mean	_
46-11	7284-7285	,	_
46-12	7286-7288	SD	_
46-13	7289-7290	)	_
46-14	7291-7292	.	_

47-1	7293-7296	The	_
47-2	7297-7302	molar	_
47-3	7303-7311	activity	_
47-4	7312-7315	was	_
47-5	7316-7319	not	_
47-6	7320-7328	analyzed	_
47-7	7329-7332	for	_
47-8	7333-7334	2	_
47-9	7335-7337	of	_
47-10	7338-7341	the	_
47-11	7342-7349	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
47-12	7350-7358	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
47-13	7359-7362	and	_
47-14	7363-7364	1	_
47-15	7365-7367	of	_
47-16	7368-7371	the	_
47-17	7372-7380	patients	_
47-18	7381-7384	due	_
47-19	7385-7387	to	_
47-20	7388-7391	the	_
47-21	7392-7397	small	_
47-22	7398-7404	amount	_
47-23	7405-7407	of	_
47-24	7408-7415	product	_
47-25	7416-7420	left	_
47-26	7421-7423	in	_
47-27	7424-7427	the	_
47-28	7428-7432	vial	_
47-29	7433-7438	after	_
47-30	7439-7448	injection	_
47-31	7449-7450	.	_

48-1	7451-7454	The	_
48-2	7455-7460	molar	_
48-3	7461-7474	radioactivity	_
48-4	7475-7478	for	_
48-5	7479-7482	the	_
48-6	7483-7492	remaining	_
48-7	7493-7495	32	_
48-8	7496-7504	subjects	_
48-9	7505-7508	was	_
48-10	7509-7512	104	_
48-11	7513-7514	±	_
48-12	7515-7518	133	_
48-13	7519-7527	MBq/nmol	_
48-14	7528-7529	,	_
48-15	7530-7535	which	_
48-16	7536-7548	corresponded	_
48-17	7549-7551	to	_
48-18	7552-7554	an	_
48-19	7555-7563	injected	_
48-20	7564-7568	mass	_
48-21	7569-7571	of	_
48-22	7572-7575	3.6	_
48-23	7576-7577	±	_
48-24	7578-7581	5.7	_
48-25	7582-7584	μg	_
48-26	7585-7586	(	_
48-27	7587-7592	range	_
48-28	7593-7600	0.17–32	_
48-29	7601-7603	μg	_
48-30	7604-7605	,	_
48-31	7606-7612	median	_
48-32	7613-7617	2.62	_
48-33	7618-7620	μg	_
48-34	7621-7622	)	_
48-35	7623-7624	.	_

49-1	7625-7628	All	_
49-2	7629-7637	subjects	_
49-3	7638-7646	received	_
49-4	7647-7648	8	_
49-5	7649-7651	μg	_
49-6	7652-7654	or	_
49-7	7655-7659	less	_
49-8	7660-7666	except	_
49-9	7667-7670	for	_
49-10	7671-7674	one	_
49-11	7675-7682	patient	_
49-12	7683-7686	who	_
49-13	7687-7695	received	_
49-14	7696-7698	32	_
49-15	7699-7701	μg	_
49-16	7702-7703	.	_

50-1	7704-7708	This	_
50-2	7709-7712	was	_
50-3	7713-7716	due	_
50-4	7717-7719	to	_
50-5	7720-7725	delay	_
50-6	7726-7728	of	_
50-7	7729-7738	injection	_
50-8	7739-7743	with	_
50-9	7744-7754	subsequent	_
50-10	7755-7763	decrease	_
50-11	7764-7766	in	_
50-12	7767-7772	molar	_
50-13	7773-7786	radioactivity	_
50-14	7787-7788	.	_

51-1	7789-7799	Estimation	_
51-2	7800-7802	of	_
51-3	7803-7806	D1R	_
51-4	7807-7816	occupancy	_
51-5	7817-7819	by	_
51-6	7820-7822	32	_
51-7	7823-7825	μg	_
51-8	7826-7834	SCH23390	_
51-9	7835-7840	based	_
51-10	7841-7843	on	_
51-11	7844-7853	published	_
51-12	7854-7858	data	_
51-13	7859-7861	is	_
51-14	7862-7865	6.0	_
51-15	7866-7867	%	_
51-16	7868-7869	,	_
51-17	7870-7874	that	_
51-18	7875-7877	is	_
51-19	7878-7879	,	_
51-20	7880-7883	the	_
51-21	7884-7891	binding	_
51-22	7892-7901	potential	_
51-23	7902-7903	(	_
51-24	7904-7908	BPND	_
51-25	7909-7910	)	_
51-26	7911-7914	was	_
51-27	7915-7929	underestimated	_
51-28	7930-7932	by	_
51-29	7933-7934	6	_
51-30	7935-7936	%	_
51-31	7937-7938	,	_
51-32	7939-7944	which	_
51-33	7945-7948	was	_
51-34	7949-7958	corrected	_
51-35	7959-7962	for	_
51-36	7963-7965	in	_
51-37	7966-7969	the	_
51-38	7970-7981	statistical	_
51-39	7982-7990	analysis	_
51-40	7991-7993	by	_
51-41	7994-8002	dividing	_
51-42	8003-8007	this	_
51-43	8008-8015	subject	_
51-44	8016-8017	’	_
51-45	8018-8019	s	_
51-46	8020-8028	subjects	_
51-47	8029-8033	BPND	_
51-48	8034-8039	value	_
51-49	8040-8042	by	_
51-50	8043-8047	0.94	_
51-51	8048-8049	.	_

52-1	8050-8053	The	_
52-2	8054-8067	radioactivity	_
52-3	8068-8071	and	_
52-4	8072-8076	mass	_
52-5	8077-8080	did	_
52-6	8081-8084	not	_
52-7	8085-8091	differ	_
52-8	8092-8105	significantly	_
52-9	8106-8113	between	_
52-10	8114-8117	the	_
52-11	8118-8126	patients	_
52-12	8127-8130	and	_
52-13	8131-8139	controls	_
52-14	8140-8141	.	_

53-1	8142-8145	The	_
53-2	8146-8149	PET	_
53-3	8150-8158	protocol	_
53-4	8159-8162	for	_
53-5	8163-8167	each	_
53-6	8168-8178	individual	_
53-7	8179-8181	is	_
53-8	8182-8188	listed	_
53-9	8189-8191	in	_
53-10	8192-8205	supplementary	_
53-11	8206-8215	Materials	_
53-12	8216-8217	2	_
53-13	8218-8219	.	_

54-1	8220-8229	Following	_
54-2	8230-8239	injection	_
54-3	8240-8241	,	_
54-4	8242-8250	emission	_
54-5	8251-8255	data	_
54-6	8256-8260	were	_
54-7	8261-8270	collected	_
54-8	8271-8273	in	_
54-9	8274-8275	a	_
54-10	8276-8284	sequence	_
54-11	8285-8287	of	_
54-12	8288-8292	time	_
54-13	8293-8299	frames	_
54-14	8300-8301	.	_

55-1	8302-8305	The	_
55-2	8306-8310	time	_
55-3	8311-8317	frames	_
55-4	8318-8320	of	_
55-5	8321-8332	acquisition	_
55-6	8333-8337	data	_
55-7	8338-8342	were	_
55-8	8343-8356	reconstructed	_
55-9	8357-8360	and	_
55-10	8361-8370	corrected	_
55-11	8371-8374	for	_
55-12	8375-8386	attenuation	_
55-13	8387-8390	and	_
55-14	8391-8398	scatter	_
55-15	8399-8404	using	_
55-16	8405-8407	2D	_
55-17	8408-8421	filtered-back	_
55-18	8422-8432	projection	_
55-19	8433-8437	into	_
55-20	8438-8439	a	_
55-21	8440-8446	series	_
55-22	8447-8449	of	_
55-23	8450-8452	3D	_
55-24	8453-8456	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
55-25	8457-8463	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
55-26	8464-8466	of	_
55-27	8467-8480	radioactivity	_
55-28	8481-8494	concentration	_
55-29	8495-8496	.	_

56-1	8497-8500	The	_
56-2	8501-8506	voxel	_
56-3	8507-8511	size	_
56-4	8512-8515	for	_
56-5	8516-8519	the	_
56-6	8520-8533	reconstructed	_
56-7	8534-8540	volume	_
56-8	8541-8544	was	_
56-9	8545-8550	2.030	_
56-10	8551-8552	×	_
56-11	8553-8558	2.030	_
56-12	8559-8560	×	_
56-13	8561-8566	3.125	_
56-14	8567-8569	mm	_
56-15	8570-8571	.	_

57-1	8572-8577	Image	_
57-2	8578-8588	Processing	_
57-3	8589-8592	and	_
57-4	8593-8607	Quantification	_
57-5	8608-8615	Despite	_
57-6	8616-8619	the	_
57-7	8620-8630	collection	_
57-8	8631-8633	of	_
57-9	8634-8638	data	_
57-10	8639-8644	being	_
57-11	8645-8654	conducted	_
57-12	8655-8659	over	_
57-13	8660-8667	several	_
57-14	8668-8673	years	_
57-15	8674-8675	,	_
57-16	8676-8679	all	_
57-17	8680-8685	image	_
57-18	8686-8696	processing	_
57-19	8697-8700	and	_
57-20	8701-8715	quantification	_
57-21	8716-8718	of	_
57-22	8719-8722	the	_
57-23	8723-8727	data	_
57-24	8728-8732	were	_
57-25	8733-8742	performed	_
57-26	8743-8745	at	_
57-27	8746-8749	the	_
57-28	8750-8754	same	_
57-29	8755-8759	time	_
57-30	8760-8766	during	_
57-31	8767-8771	2018	_
57-32	8772-8777	using	_
57-33	8778-8785	current	_
57-34	8786-8794	analysis	_
57-35	8795-8803	software	_
57-36	8804-8805	.	_

58-1	8806-8823	Three-dimensional	_
58-2	8824-8827	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
58-3	8828-8834	images	_
58-4	8835-8839	were	_
58-5	8840-8843	for	_
58-6	8844-8848	each	_
58-7	8849-8853	time	_
58-8	8854-8859	frame	_
58-9	8860-8869	corrected	_
58-10	8870-8873	for	_
58-11	8874-8878	head	_
58-12	8879-8885	motion	_
58-13	8886-8891	using	_
58-14	8892-8893	a	_
58-15	8894-8912	postreconstruction	_
58-16	8913-8927	frame-by-frame	_
58-17	8928-8939	realignment	_
58-18	8940-8949	algorithm	_
58-19	8950-8951	,	_
58-20	8952-8954	in	_
58-21	8955-8960	which	_
58-22	8961-8964	the	_
58-23	8965-8972	dynamic	_
58-24	8973-8976	PET	_
58-25	8977-8982	image	_
58-26	8983-8986	was	_
58-27	8987-8992	first	_
58-28	8993-9000	divided	_
58-29	9001-9005	into	_
58-30	9006-9012	blocks	_
58-31	9013-9015	of	_
58-32	9016-9022	frames	_
58-33	9023-9025	of	_
58-34	9026-9027	a	_
58-35	9028-9034	minute	_
58-36	9035-9037	or	_
58-37	9038-9044	longer	_
58-38	9045-9046	,	_
58-39	9047-9051	that	_
58-40	9052-9054	is	_
58-41	9055-9056	,	_
58-42	9057-9063	frames	_
58-43	9064-9066	of	_
58-44	9067-9071	less	_
58-45	9072-9076	than	_
58-46	9077-9078	a	_
58-47	9079-9085	minute	_
58-48	9086-9090	were	_
58-49	9091-9097	summed	_
58-50	9098-9106	together	_
58-51	9107-9108	.	_

59-1	9109-9113	Then	_
59-2	9114-9117	all	_
59-3	9118-9124	images	_
59-4	9125-9129	were	_
59-5	9130-9142	individually	_
59-6	9143-9150	aligned	_
59-7	9151-9153	to	_
59-8	9154-9157	the	_
59-9	9158-9163	first	_
59-10	9164-9170	minute	_
59-11	9171-9173	of	_
59-12	9174-9185	acquisition	_
59-13	9186-9191	using	_
59-14	9192-9195	the	_
59-15	9196-9200	SPM5	_
59-16	9201-9202	(	_
59-17	9203-9211	Wellcome	_
59-18	9212-9222	Department	_
59-19	9223-9225	of	_
59-20	9226-9235	Cognitive	_
59-21	9236-9245	Neurology	_
59-22	9246-9247	,	_
59-23	9248-9258	University	_
59-24	9259-9266	College	_
59-25	9267-9273	London	_
59-26	9274-9275	)	_
59-27	9276-9277	.	_

60-1	9278-9286	Integral	_
60-2	9287-9290	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
60-3	9291-9297	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
60-4	9298-9302	were	_
60-5	9303-9310	created	_
60-6	9311-9316	using	_
60-7	9317-9324	ecatsum	_
60-8	9325-9326	(	_
60-9	9327-9328	v	_
60-10	9329-9334	1.4.3	_
60-11	9335-9336	,	_
60-12	9337-9342	Turku	_
60-13	9343-9346	PET	_
60-14	9347-9353	Centre	_
60-15	9354-9355	)	_
60-16	9356-9357	.	_

61-1	9358-9365	Finally	_
61-2	9366-9367	,	_
61-3	9368-9370	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
61-4	9371-9377	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
61-5	9378-9382	were	_
61-6	9383-9393	reoriented	_
61-7	9394-9398	into	_
61-8	9399-9402	the	_
61-9	9403-9408	AC-PC	_
61-10	9409-9414	plane	_
61-11	9415-9418	and	_
61-12	9419-9431	coregistered	_
61-13	9432-9434	to	_
61-14	9435-9443	integral	_
61-15	9444-9447	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
61-16	9448-9454	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
61-17	9455-9460	using	_
61-18	9461-9465	SPM5	_
61-19	9466-9467	.	_

62-1	9468-9475	Kinetic	_
62-2	9476-9485	modelling	_
62-3	9486-9489	was	_
62-4	9490-9499	performed	_
62-5	9500-9505	using	_
62-6	9506-9509	the	_
62-7	9510-9511	R	_
62-8	9512-9519	package	_
62-9	9520-9527	kinfitr	_
62-10	9528-9529	(	_
62-11	9530-9531	v	_
62-12	9532-9537	0.2.0	_
62-13	9538-9539	)	_
62-14	9540-9541	(	_
62-15	9542-9547	https	_
62-16	9548-9549	:	_
62-17	9550-9580	//github.com/mathesong/kinfitr	_
62-18	9581-9582	)	_
62-19	9583-9584	.	_

63-1	9585-9593	Regional	_
63-2	9594-9598	BPND	_
63-3	9599-9605	values	_
63-4	9606-9610	were	_
63-5	9611-9621	calculated	_
63-6	9622-9627	using	_
63-7	9628-9631	the	_
63-8	9632-9642	simplified	_
63-9	9643-9652	reference	_
63-10	9653-9659	tissue	_
63-11	9660-9665	model	_
63-12	9666-9670	with	_
63-13	9671-9674	the	_
63-14	9675-9685	cerebellar	_
63-15	9686-9690	grey	_
63-16	9691-9697	matter	_
63-17	9698-9700	as	_
63-18	9701-9710	reference	_
63-19	9711-9717	region	_
63-20	9718-9719	.	_

64-1	9720-9723	ROI	_
64-2	9724-9735	Delineation	_
64-3	9736-9739	The	_
64-4	9740-9742	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-5	9743-9749	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-6	9750-9754	were	_
64-7	9755-9759	used	_
64-8	9760-9762	to	_
64-9	9763-9772	delineate	_
64-10	9773-9783	anatomical	_
64-11	9784-9788	ROIs	_
64-12	9789-9792	for	_
64-13	9793-9796	the	_
64-14	9797-9805	striatum	_
64-15	9806-9807	(	_
64-16	9808-9811	STR	_
64-17	9812-9813	)	_
64-18	9814-9815	(	_
64-19	9816-9823	caudate	_
64-20	9824-9827	and	_
64-21	9828-9835	putamen	_
64-22	9836-9837	)	_
64-23	9838-9839	,	_
64-24	9840-9843	the	_
64-25	9844-9856	dorsolateral	_
64-26	9857-9867	prefrontal	_
64-27	9868-9874	cortex	_
64-28	9875-9876	(	_
64-29	9877-9882	DLPFC	_
64-30	9883-9884	)	_
64-31	9885-9888	and	_
64-32	9889-9892	the	_
64-33	9893-9903	cerebellum	_
64-34	9904-9905	(	_
64-35	9906-9909	CBL	_
64-36	9910-9911	)	_
64-37	9912-9913	.	_

65-1	9914-9917	The	_
65-2	9918-9921	STR	_
65-3	9922-9925	and	_
65-4	9926-9931	DLPFC	_
65-5	9932-9936	were	_
65-6	9937-9943	chosen	_
65-7	9944-9949	since	_
65-8	9950-9954	they	_
65-9	9955-9958	are	_
65-10	9959-9966	regions	_
65-11	9967-9969	of	_
65-12	9970-9977	central	_
65-13	9978-9986	interest	_
65-14	9987-9989	in	_
65-15	9990-10003	schizophrenia	_
65-16	10004-10012	research	_
65-17	10013-10014	.	_

66-1	10015-10018	For	_
66-2	10019-10022	the	_
66-3	10023-10028	DLPFC	_
66-4	10029-10030	,	_
66-5	10031-10038	several	_
66-6	10039-10049	convergent	_
66-7	10050-10058	findings	_
66-8	10059-10067	relevant	_
66-9	10068-10071	for	_
66-10	10072-10085	schizophrenia	_
66-11	10086-10089	and	_
66-12	10090-10093	D1R	_
66-13	10094-10106	transmission	_
66-14	10107-10111	have	_
66-15	10112-10116	been	_
66-16	10117-10125	reported	_
66-17	10126-10127	.	_

67-1	10128-10130	In	_
67-2	10131-10139	addition	_
67-3	10140-10141	,	_
67-4	10142-10144	we	_
67-5	10145-10154	performed	_
67-6	10155-10157	an	_
67-7	10158-10169	exploratory	_
67-8	10170-10178	analysis	_
67-9	10179-10181	of	_
67-10	10182-10192	additional	_
67-11	10193-10201	cortical	_
67-12	10202-10218	regions—anterior	_
67-13	10219-10228	cingulate	_
67-14	10229-10235	cortex	_
67-15	10236-10237	(	_
67-16	10238-10241	ACC	_
67-17	10242-10243	)	_
67-18	10244-10245	,	_
67-19	10246-10254	temporal	_
67-20	10255-10261	cortex	_
67-21	10262-10263	(	_
67-22	10264-10266	TC	_
67-23	10267-10268	)	_
67-24	10269-10270	,	_
67-25	10271-10277	medial	_
67-26	10278-10288	prefrontal	_
67-27	10289-10295	cortex	_
67-28	10296-10297	(	_
67-29	10298-10302	MPFC	_
67-30	10303-10304	)	_
67-31	10305-10306	,	_
67-32	10307-10310	and	_
67-33	10311-10317	orbito	_
67-34	10318-10325	frontal	_
67-35	10326-10332	cortex	_
67-36	10333-10334	(	_
67-37	10335-10338	OFC	_
67-38	10339-10340	)	_
67-39	10341-10347	—based	_
67-40	10348-10350	on	_
67-41	10351-10359	previous	_
67-42	10360-10367	studies	_
67-43	10368-10381	investigating	_
67-44	10382-10386	D1-R	_
67-45	10387-10389	in	_
67-46	10390-10399	psychosis	_
67-47	10400-10401	.	_

68-1	10402-10405	The	_
68-2	10406-10409	CBL	_
68-3	10410-10413	was	_
68-4	10414-10420	chosen	_
68-5	10421-10423	as	_
68-6	10424-10433	reference	_
68-7	10434-10440	region	_
68-8	10441-10444	for	_
68-9	10445-10448	the	_
68-10	10449-10462	concentration	_
68-11	10463-10465	of	_
68-12	10466-10470	free	_
68-13	10471-10474	and	_
68-14	10475-10490	nonspecifically	_
68-15	10491-10496	bound	_
68-16	10497-10498	[	_
68-17	10499-10502	11C	_
68-18	10503-10504	]	_
68-19	10505-10513	SCH23390	_
68-20	10514-10515	.	_

69-1	10516-10520	Grey	_
69-2	10521-10527	matter	_
69-3	10528-10529	,	_
69-4	10530-10535	white	_
69-5	10536-10542	matter	_
69-6	10543-10544	,	_
69-7	10545-10548	and	_
69-8	10549-10552	CSF	_
69-9	10553-10557	were	_
69-10	10558-10567	segmented	_
69-11	10568-10573	using	_
69-12	10574-10577	the	_
69-13	10578-10582	SPM5	_
69-14	10583-10590	Unified	_
69-15	10591-10602	Segmetation	_
69-16	10603-10610	routine	_
69-17	10611-10613	on	_
69-18	10614-10618	both	_
69-19	10619-10621	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
69-20	10622-10625	and	_
69-21	10626-10628	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
69-22	10629-10631	MR	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
69-23	10632-10638	images	_
69-24	10639-10640	.	_

70-1	10641-10646	These	_
70-2	10647-10651	maps	_
70-3	10652-10656	were	_
70-4	10657-10661	used	_
70-5	10662-10664	to	_
70-6	10665-10669	mask	_
70-7	10670-10674	ROIs	_
70-8	10675-10676	.	_

71-1	10677-10680	For	_
71-2	10681-10684	the	_
71-3	10685-10691	manual	_
71-4	10692-10698	method	_
71-5	10699-10700	,	_
71-6	10701-10703	an	_
71-7	10704-10712	in-house	_
71-8	10713-10721	software	_
71-9	10722-10723	,	_
71-10	10724-10727	HBA	_
71-11	10728-10729	,	_
71-12	10730-10733	was	_
71-13	10734-10738	used	_
71-14	10739-10744	where	_
71-15	10745-10748	the	_
71-16	10749-10751	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
71-17	10752-10758	images	_
71-18	10759-10763	were	_
71-19	10764-10770	loaded	_
71-20	10771-10775	into	_
71-21	10776-10777	a	_
71-22	10778-10781	3-D	_
71-23	10782-10788	volume	_
71-24	10789-10792	for	_
71-25	10793-10804	delineation	_
71-26	10805-10807	of	_
71-27	10808-10811	the	_
71-28	10812-10816	ROIs	_
71-29	10817-10819	on	_
71-30	10820-10821	1	_
71-31	10822-10824	of	_
71-32	10825-10828	the	_
71-33	10829-10830	3	_
71-34	10831-10841	orthogonal	_
71-35	10842-10853	projections	_
71-36	10854-10858	with	_
71-37	10859-10863	1-mm	_
71-38	10864-10869	slice	_
71-39	10870-10879	thickness	_
71-40	10880-10881	.	_

72-1	10882-10885	The	_
72-2	10886-10892	manual	_
72-3	10893-10905	segmentation	_
72-4	10906-10909	was	_
72-5	10910-10919	performed	_
72-6	10920-10922	by	_
72-7	10923-10926	one	_
72-8	10927-10939	investigator	_
72-9	10940-10947	blinded	_
72-10	10948-10950	to	_
72-11	10951-10958	patient	_
72-12	10959-10965	status	_
72-13	10966-10967	(	_
72-14	10968-10971	P.S	_
72-15	10972-10973	.	_
72-16	10974-10975	)	_

73-1	10976-10979	who	_
73-2	10980-10983	has	_
73-3	10984-10988	more	_
73-4	10989-10993	than	_
73-5	10994-10996	20	_
73-6	10997-11002	years	_
73-7	11003-11005	of	_
73-8	11006-11016	experience	_
73-9	11017-11019	in	_
73-10	11020-11026	manual	_
73-11	11027-11030	ROI	_
73-12	11031-11042	delineation	_
73-13	11043-11044	.	_

74-1	11045-11048	The	_
74-2	11049-11056	caudate	_
74-3	11057-11060	and	_
74-4	11061-11068	putamen	_
74-5	11069-11073	were	_
74-6	11074-11084	delineated	_
74-7	11085-11087	as	_
74-8	11088-11097	described	_
74-9	11098-11100	by	_
74-10	11101-11105	with	_
74-11	11106-11109	the	_
74-12	11110-11122	modification	_
74-13	11123-11127	that	_
74-14	11128-11131	the	_
74-15	11132-11140	sagittal	_
74-16	11141-11147	planes	_
74-17	11148-11152	were	_
74-18	11153-11157	used	_
74-19	11158-11165	instead	_
74-20	11166-11168	of	_
74-21	11169-11172	the	_
74-22	11173-11180	coronal	_
74-23	11181-11182	.	_

75-1	11183-11186	The	_
75-2	11187-11194	ventral	_
75-3	11195-11203	striatum	_
75-4	11204-11207	was	_
75-5	11208-11211	not	_
75-6	11212-11220	included	_
75-7	11221-11222	.	_

76-1	11223-11226	The	_
76-2	11227-11232	DLPFC	_
76-3	11233-11234	,	_
76-4	11235-11239	MPFC	_
76-5	11240-11241	,	_
76-6	11242-11245	and	_
76-7	11246-11249	OFC	_
76-8	11250-11254	were	_
76-9	11255-11261	traced	_
76-10	11262-11264	on	_
76-11	11265-11267	20	_
76-12	11268-11275	coronal	_
76-13	11276-11282	planes	_
76-14	11283-11291	anterior	_
76-15	11292-11294	to	_
76-16	11295-11298	the	_
76-17	11299-11303	genu	_
76-18	11304-11306	of	_
76-19	11307-11310	the	_
76-20	11311-11317	corpus	_
76-21	11318-11326	callosum	_
76-22	11327-11328	.	_

77-1	11329-11332	The	_
77-2	11333-11341	anterior	_
77-3	11342-11351	cingulate	_
77-4	11352-11358	cortex	_
77-5	11359-11362	and	_
77-6	11363-11371	temporal	_
77-7	11372-11378	cortex	_
77-8	11379-11383	were	_
77-9	11384-11390	traced	_
77-10	11391-11393	on	_
77-11	11394-11402	sagittal	_
77-12	11403-11409	planes	_
77-13	11410-11412	in	_
77-14	11413-11418	their	_
77-15	11419-11427	entirety	_
77-16	11428-11429	.	_

78-1	11430-11433	The	_
78-2	11434-11442	cortical	_
78-3	11443-11450	regions	_
78-4	11451-11455	were	_
78-5	11456-11462	masked	_
78-6	11463-11465	by	_
78-7	11466-11469	the	_
78-8	11470-11472	GM	_
78-9	11473-11476	map	_
78-10	11477-11480	for	_
78-11	11481-11491	gray-white	_
78-12	11492-11498	matter	_
78-13	11499-11511	segmentation	_
78-14	11512-11513	.	_

79-1	11514-11517	The	_
79-2	11518-11528	cerebellum	_
79-3	11529-11532	was	_
79-4	11533-11538	drawn	_
79-5	11539-11541	on	_
79-6	11542-11545	the	_
79-7	11546-11553	central	_
79-8	11554-11555	6	_
79-9	11556-11566	transaxial	_
79-10	11567-11573	planes	_
79-11	11574-11576	of	_
79-12	11577-11580	the	_
79-13	11581-11591	cerebellum	_
79-14	11592-11595	and	_
79-15	11596-11601	about	_
79-16	11602-11603	1	_
79-17	11604-11606	cm	_
79-18	11607-11614	distant	_
79-19	11615-11619	from	_
79-20	11620-11623	the	_
79-21	11624-11638	subarachnoidal	_
79-22	11639-11644	space	_
79-23	11645-11646	.	_

80-1	11647-11650	The	_
80-2	11651-11655	ROIs	_
80-3	11656-11660	were	_
80-4	11661-11671	translated	_
80-5	11672-11676	into	_
80-6	11677-11680	the	_
80-7	11681-11691	respective	_
80-8	11692-11695	PET	_
80-9	11696-11701	image	_
80-10	11702-11707	space	_
80-11	11708-11713	using	_
80-12	11714-11717	the	_
80-13	11718-11732	inter-modality	_
80-14	11733-11747	coregistration	_
80-15	11748-11756	matrices	_
80-16	11757-11758	.	_

81-1	11759-11770	Statistical	_
81-2	11771-11779	Analysis	_
81-3	11780-11783	The	_
81-4	11784-11787	aim	_
81-5	11788-11791	was	_
81-6	11792-11794	to	_
81-7	11795-11802	compare	_
81-8	11803-11807	BPND	_
81-9	11808-11815	between	_
81-10	11816-11823	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
81-11	11824-11832	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
81-12	11833-11836	and	_
81-13	11837-11850	first-episode	_
81-14	11851-11860	psychosis	_
81-15	11861-11869	patients	_
81-16	11870-11871	.	_

82-1	11872-11881	Inference	_
82-2	11882-11885	was	_
82-3	11886-11895	performed	_
82-4	11896-11901	using	_
82-5	11902-11906	both	_
82-6	11907-11918	frequentist	_
82-7	11919-11926	methods	_
82-8	11927-11928	(	_
82-9	11929-11933	i.e.	_
82-10	11934-11935	,	_
82-11	11936-11937	P	_
82-12	11938-11944	values	_
82-13	11945-11946	)	_
82-14	11947-11949	as	_
82-15	11950-11954	well	_
82-16	11955-11957	as	_
82-17	11958-11966	Bayesian	_
82-18	11967-11977	hypothesis	_
82-19	11978-11985	testing	_
82-20	11986-11993	methods	_
82-21	11994-11995	.	_

83-1	11996-11999	For	_
83-2	12000-12004	both	_
83-3	12005-12013	analyses	_
83-4	12014-12015	,	_
83-5	12016-12018	we	_
83-6	12019-12027	included	_
83-7	12028-12031	age	_
83-8	12032-12034	in	_
83-9	12035-12038	the	_
83-10	12039-12049	regression	_
83-11	12050-12055	model	_
83-12	12056-12057	,	_
83-13	12058-12060	as	_
83-14	12061-12063	an	_
83-15	12064-12067	age	_
83-16	12068-12074	effect	_
83-17	12075-12077	on	_
83-18	12078-12079	[	_
83-19	12080-12083	11C	_
83-20	12084-12085	]	_
83-21	12086-12094	SCH23390	_
83-22	12095-12099	BPND	_
83-23	12100-12103	has	_
83-24	12104-12116	consistently	_
83-25	12117-12121	been	_
83-26	12122-12130	reported	_
83-27	12131-12132	.	_

84-1	12133-12136	For	_
84-2	12137-12140	the	_
84-3	12141-12152	frequentist	_
84-4	12153-12159	models	_
84-5	12160-12161	,	_
84-6	12162-12165	age	_
84-7	12166-12169	was	_
84-8	12170-12177	entered	_
84-9	12178-12180	as	_
84-10	12181-12182	a	_
84-11	12183-12192	covariate	_
84-12	12193-12195	in	_
84-13	12196-12199	the	_
84-14	12200-12208	multiple	_
84-15	12209-12215	linear	_
84-16	12216-12226	regression	_
84-17	12227-12233	models	_
84-18	12234-12235	.	_

85-1	12236-12239	For	_
85-2	12240-12243	the	_
85-3	12244-12252	Bayesian	_
85-4	12253-12259	models	_
85-5	12260-12261	,	_
85-6	12262-12264	we	_
85-7	12265-12272	defined	_
85-8	12273-12284	informative	_
85-9	12285-12291	priors	_
85-10	12292-12295	for	_
85-11	12296-12299	the	_
85-12	12300-12312	relationship	_
85-13	12313-12320	between	_
85-14	12321-12324	age	_
85-15	12325-12328	and	_
85-16	12329-12330	[	_
85-17	12331-12334	11C	_
85-18	12335-12336	]	_
85-19	12337-12345	SCH23390	_
85-20	12346-12350	BPND	_
85-21	12351-12356	based	_
85-22	12357-12359	on	_
85-23	12360-12361	a	_
85-24	12362-12370	weighted	_
85-25	12371-12378	average	_
85-26	12379-12381	of	_
85-27	12382-12385	the	_
85-28	12386-12393	results	_
85-29	12394-12396	of	_
85-30	12397-12405	previous	_
85-31	12406-12413	studies	_
85-32	12414-12423	examining	_
85-33	12424-12428	this	_
85-34	12429-12440	association	_
85-35	12441-12442	.	_

86-1	12443-12447	This	_
86-2	12448-12457	procedure	_
86-3	12458-12467	functions	_
86-4	12468-12470	to	_
86-5	12471-12482	essentially	_
86-6	12483-12492	constrain	_
86-7	12493-12496	the	_
86-8	12497-12502	model	_
86-9	12503-12505	to	_
86-10	12506-12512	likely	_
86-11	12513-12519	values	_
86-12	12520-12522	of	_
86-13	12523-12526	the	_
86-14	12527-12536	parameter	_
86-15	12537-12547	estimating	_
86-16	12548-12551	the	_
86-17	12552-12558	effect	_
86-18	12559-12561	of	_
86-19	12562-12565	age	_
86-20	12566-12568	on	_
86-21	12569-12570	[	_
86-22	12571-12574	11C	_
86-23	12575-12576	]	_
86-24	12577-12585	SCH23390	_
86-25	12586-12590	BPND	_
86-26	12591-12596	based	_
86-27	12597-12599	on	_
86-28	12600-12608	previous	_
86-29	12609-12616	reports	_
86-30	12617-12618	.	_

87-1	12619-12623	This	_
87-2	12624-12633	procedure	_
87-3	12634-12640	limits	_
87-4	12641-12644	the	_
87-5	12645-12654	influence	_
87-6	12655-12657	of	_
87-7	12658-12669	uncertainty	_
87-8	12670-12672	in	_
87-9	12673-12676	the	_
87-10	12677-12687	estimation	_
87-11	12688-12690	of	_
87-12	12691-12694	the	_
87-13	12695-12706	association	_
87-14	12707-12714	between	_
87-15	12715-12718	age	_
87-16	12719-12722	and	_
87-17	12723-12730	binding	_
87-18	12731-12740	estimated	_
87-19	12741-12743	in	_
87-20	12744-12748	this	_
87-21	12749-12759	particular	_
87-22	12760-12767	dataset	_
87-23	12768-12769	,	_
87-24	12770-12775	which	_
87-25	12776-12781	might	_
87-26	12782-12791	otherwise	_
87-27	12792-12798	affect	_
87-28	12799-12808	estimates	_
87-29	12809-12811	of	_
87-30	12812-12815	the	_
87-31	12816-12822	effect	_
87-32	12823-12825	of	_
87-33	12826-12835	psychosis	_
87-34	12836-12838	on	_
87-35	12839-12846	binding	_
87-36	12847-12856	estimates	_
87-37	12857-12858	.	_

88-1	12859-12863	This	_
88-2	12864-12869	prior	_
88-3	12870-12873	was	_
88-4	12874-12887	parameterized	_
88-5	12888-12890	as	_
88-6	12891-12898	follows	_
88-7	12899-12900	:	_
88-8	12901-12904	for	_
88-9	12905-12908	the	_
88-10	12909-12914	DLPFC	_
88-11	12915-12916	,	_
88-12	12917-12921	mean	_
88-13	12922-12923	=	_
88-14	12924-12929	−1.56	_
88-15	12930-12931	%	_
88-16	12932-12935	per	_
88-17	12936-12940	year	_
88-18	12941-12942	,	_
88-19	12943-12945	SD	_
88-20	12946-12947	=	_
88-21	12948-12952	0.66	_
88-22	12953-12954	%	_
88-23	12955-12956	;	_
88-24	12957-12960	for	_
88-25	12961-12964	the	_
88-26	12965-12968	STR	_
88-27	12969-12970	,	_
88-28	12971-12975	mean	_
88-29	12976-12977	=	_
88-30	12978-12983	−0.76	_
88-31	12984-12985	%	_
88-32	12986-12989	per	_
88-33	12990-12994	year	_
88-34	12995-12996	,	_
88-35	12997-12999	SD	_
88-36	13000-13001	=	_
88-37	13002-13006	0.04	_
88-38	13007-13008	%	_
88-39	13009-13010	.	_

89-1	13011-13014	For	_
89-2	13015-13018	the	_
89-3	13019-13029	assessment	_
89-4	13030-13032	of	_
89-5	13033-13036	the	_
89-6	13037-13046	influence	_
89-7	13047-13049	of	_
89-8	13050-13057	patient	_
89-9	13058-13064	status	_
89-10	13065-13066	,	_
89-11	13067-13069	we	_
89-12	13070-13078	tailored	_
89-13	13079-13082	our	_
89-14	13083-13094	statistical	_
89-15	13095-13101	models	_
89-16	13102-13107	based	_
89-17	13108-13110	on	_
89-18	13111-13114	the	_
89-19	13115-13120	mixed	_
89-20	13121-13128	results	_
89-21	13129-13131	in	_
89-22	13132-13140	previous	_
89-23	13141-13149	clinical	_
89-24	13150-13153	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
89-25	13154-13161	studies	_
89-26	13162-13171	assessing	_
89-27	13172-13183	differences	_
89-28	13184-13186	in	_
89-29	13187-13190	D1R	_
89-30	13191-13203	availability	_
89-31	13204-13211	between	_
89-32	13212-13225	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
89-33	13226-13234	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
89-34	13235-13238	and	_
89-35	13239-13247	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
89-36	13248-13249	.	_

90-1	13250-13253	For	_
90-2	13254-13257	the	_
90-3	13258-13269	frequentist	_
90-4	13270-13278	analysis	_
90-5	13279-13280	,	_
90-6	13281-13283	we	_
90-7	13284-13288	made	_
90-8	13289-13292	use	_
90-9	13293-13295	of	_
90-10	13296-13297	a	_
90-11	13298-13305	2-sided	_
90-12	13306-13310	test	_
90-13	13311-13312	,	_
90-14	13313-13316	due	_
90-15	13317-13319	to	_
90-16	13320-13323	the	_
90-17	13324-13329	mixed	_
90-18	13330-13337	results	_
90-19	13338-13339	,	_
90-20	13340-13345	using	_
90-21	13346-13348	an	_
90-22	13349-13354	alpha	_
90-23	13355-13357	of	_
90-24	13358-13362	0.05	_
90-25	13363-13364	.	_

91-1	13365-13368	For	_
91-2	13369-13372	the	_
91-3	13373-13381	Bayesian	_
91-4	13382-13390	analysis	_
91-5	13391-13392	,	_
91-6	13393-13395	we	_
91-7	13396-13400	made	_
91-8	13401-13404	use	_
91-9	13405-13407	of	_
91-10	13408-13416	Bayesian	_
91-11	13417-13427	hypothesis	_
91-12	13428-13435	testing	_
91-13	13436-13437	(	_
91-14	13438-13442	i.e.	_
91-15	13443-13444	,	_
91-16	13445-13450	Bayes	_
91-17	13451-13458	Factors	_
91-18	13459-13460	,	_
91-19	13461-13464	BFs	_
91-20	13465-13466	)	_
91-21	13467-13469	to	_
91-22	13470-13477	compare	_
91-23	13478-13481	the	_
91-24	13482-13490	relative	_
91-25	13491-13503	plausibility	_
91-26	13504-13506	of	_
91-27	13507-13515	separate	_
91-28	13516-13526	hypotheses	_
91-29	13527-13528	:	_
91-30	13529-13531	of	_
91-31	13532-13538	higher	_
91-32	13539-13542	and	_
91-33	13543-13548	lower	_
91-34	13549-13550	[	_
91-35	13551-13554	11C	_
91-36	13555-13556	]	_
91-37	13557-13565	SCH23390	_
91-38	13566-13570	BPND	_
91-39	13571-13572	,	_
91-40	13573-13585	respectively	_
91-41	13586-13587	,	_
91-42	13588-13590	in	_
91-43	13591-13599	patients	_
91-44	13600-13608	compared	_
91-45	13609-13614	wiith	_
91-46	13615-13623	controls	_
91-47	13624-13625	.	_

92-1	13626-13629	For	_
92-2	13630-13633	the	_
92-3	13634-13645	differences	_
92-4	13646-13653	between	_
92-5	13654-13662	patients	_
92-6	13663-13666	and	_
92-7	13667-13675	controls	_
92-8	13676-13677	,	_
92-9	13678-13680	we	_
92-10	13681-13688	defined	_
92-11	13689-13696	1-sided	_
92-12	13697-13708	half-normal	_
92-13	13709-13722	distributions	_
92-14	13723-13726	for	_
92-15	13727-13730	the	_
92-16	13731-13741	hypotheses	_
92-17	13742-13744	of	_
92-18	13745-13754	increased	_
92-19	13755-13758	and	_
92-20	13759-13768	decreased	_
92-21	13769-13773	BPND	_
92-22	13774-13776	in	_
92-23	13777-13785	patients	_
92-24	13786-13794	compared	_
92-25	13795-13799	with	_
92-26	13800-13808	controls	_
92-27	13809-13810	,	_
92-28	13811-13823	respectively	_
92-29	13824-13825	,	_
92-30	13826-13830	from	_
92-31	13831-13839	previous	_
92-32	13840-13847	studies	_
92-33	13848-13853	using	_
92-34	13854-13855	[	_
92-35	13856-13859	11C	_
92-36	13860-13861	]	_
92-37	13862-13870	SCH23390	_
92-38	13871-13875	BPND	_
92-39	13876-13877	.	_

93-1	13878-13886	Previous	_
93-2	13887-13894	studies	_
93-3	13895-13901	making	_
93-4	13902-13905	use	_
93-5	13906-13908	of	_
93-6	13909-13910	[	_
93-7	13911-13914	11C	_
93-8	13915-13916	]	_
93-9	13917-13923	NNC112	_
93-10	13924-13928	were	_
93-11	13929-13932	not	_
93-12	13933-13941	included	_
93-13	13942-13943	,	_
93-14	13944-13946	as	_
93-15	13947-13950	the	_
93-16	13951-13961	percentage	_
93-17	13962-13968	change	_
93-18	13969-13972	may	_
93-19	13973-13976	not	_
93-20	13977-13979	be	_
93-21	13980-13988	directly	_
93-22	13989-13999	applicable	_
93-23	14000-14002	to	_
93-24	14003-14004	[	_
93-25	14005-14008	11C	_
93-26	14009-14010	]	_
93-27	14011-14019	SCH23390	_
93-28	14020-14024	BPND	_
93-29	14025-14028	for	_
93-30	14029-14036	several	_
93-31	14037-14044	reasons	_
93-32	14045-14046	.	_

94-1	14047-14052	First	_
94-2	14053-14054	,	_
94-3	14055-14056	[	_
94-4	14057-14060	11C	_
94-5	14061-14062	]	_
94-6	14063-14069	NNC112	_
94-7	14070-14073	has	_
94-8	14074-14075	a	_
94-9	14076-14089	significantly	_
94-10	14090-14096	higher	_
94-11	14097-14105	affinity	_
94-12	14106-14109	for	_
94-13	14110-14113	the	_
94-14	14114-14117	D1R	_
94-15	14118-14119	.	_

95-1	14120-14126	Second	_
95-2	14127-14128	,	_
95-3	14129-14132	for	_
95-4	14133-14137	both	_
95-5	14138-14150	radioligands	_
95-6	14151-14157	5-HT2A	_
95-7	14158-14166	receptor	_
95-8	14167-14174	binding	_
95-9	14175-14186	contributes	_
95-10	14187-14189	to	_
95-11	14190-14191	a	_
95-12	14192-14205	nonnegligible	_
95-13	14206-14214	fraction	_
95-14	14215-14217	of	_
95-15	14218-14226	cortical	_
95-16	14227-14234	binding	_
95-17	14235-14236	,	_
95-18	14237-14240	and	_
95-19	14241-14252	differences	_
95-20	14253-14255	in	_
95-21	14256-14260	this	_
95-22	14261-14269	fraction	_
95-23	14270-14275	might	_
95-24	14276-14281	cause	_
95-25	14282-14292	systematic	_
95-26	14293-14304	differences	_
95-27	14305-14306	.	_

96-1	14307-14315	Although	_
96-2	14316-14320	this	_
96-3	14321-14329	fraction	_
96-4	14330-14333	has	_
96-5	14334-14338	been	_
96-6	14339-14344	shown	_
96-7	14345-14347	to	_
96-8	14348-14350	be	_
96-9	14351-14358	similar	_
96-10	14359-14361	in	_
96-11	14362-14371	magnitude	_
96-12	14372-14375	for	_
96-13	14376-14380	both	_
96-14	14381-14388	tracers	_
96-15	14389-14390	,	_
96-16	14391-14394	for	_
96-17	14395-14396	[	_
96-18	14397-14400	11C	_
96-19	14401-14402	]	_
96-20	14403-14411	SCH23390	_
96-21	14412-14416	this	_
96-22	14417-14425	estimate	_
96-23	14426-14429	was	_
96-24	14430-14437	derived	_
96-25	14438-14442	from	_
96-26	14443-14444	a	_
96-27	14445-14448	PET	_
96-28	14449-14460	examination	_
96-29	14461-14463	of	_
96-30	14464-14468	only	_
96-31	14469-14470	2	_
96-32	14471-14478	baboons	_
96-33	14479-14482	and	_
96-34	14483-14486	not	_
96-35	14487-14491	from	_
96-36	14492-14498	humans	_
96-37	14499-14500	.	_

97-1	14501-14507	Lastly	_
97-2	14508-14509	,	_
97-3	14510-14512	in	_
97-4	14513-14520	studies	_
97-5	14521-14526	using	_
97-6	14527-14528	[	_
97-7	14529-14532	11C	_
97-8	14533-14534	]	_
97-9	14535-14541	NNC112	_
97-10	14542-14543	,	_
97-11	14544-14547	the	_
97-12	14548-14552	main	_
97-13	14553-14560	outcome	_
97-14	14561-14570	parameter	_
97-15	14571-14574	has	_
97-16	14575-14579	been	_
97-17	14580-14583	BPP	_
97-18	14584-14585	,	_
97-19	14586-14590	with	_
97-20	14591-14595	BPND	_
97-21	14596-14606	calculated	_
97-22	14607-14609	in	_
97-23	14610-14613	all	_
97-24	14614-14619	cases	_
97-25	14620-14623	but	_
97-26	14624-14627	one	_
97-27	14628-14633	using	_
97-28	14634-14642	arterial	_
97-29	14643-14649	plasma	_
97-30	14650-14662	measurements	_
97-31	14663-14664	.	_

98-1	14665-14667	To	_
98-2	14668-14674	assure	_
98-3	14675-14679	that	_
98-4	14680-14685	these	_
98-5	14686-14696	hypotheses	_
98-6	14697-14701	were	_
98-7	14702-14705	not	_
98-8	14706-14720	differentially	_
98-9	14721-14731	influenced	_
98-10	14732-14734	by	_
98-11	14735-14744	different	_
98-12	14745-14750	sizes	_
98-13	14751-14753	of	_
98-14	14754-14764	previously	_
98-15	14765-14773	reported	_
98-16	14774-14781	effects	_
98-17	14782-14783	,	_
98-18	14784-14786	we	_
98-19	14787-14792	opted	_
98-20	14793-14795	to	_
98-21	14796-14799	use	_
98-22	14800-14803	the	_
98-23	14804-14808	same	_
98-24	14809-14814	scale	_
98-25	14815-14818	for	_
98-26	14819-14823	both	_
98-27	14824-14827	the	_
98-28	14828-14836	increase	_
98-29	14837-14840	and	_
98-30	14841-14849	decrease	_
98-31	14850-14855	prior	_
98-32	14856-14861	based	_
98-33	14862-14864	on	_
98-34	14865-14866	a	_
98-35	14867-14875	weighted	_
98-36	14876-14883	average	_
98-37	14884-14886	of	_
98-38	14887-14895	previous	_
98-39	14896-14907	differences	_
98-40	14908-14909	.	_

99-1	14910-14912	We	_
99-2	14913-14922	therefore	_
99-3	14923-14927	used	_
99-4	14928-14929	a	_
99-5	14930-14932	SD	_
99-6	14933-14935	of	_
99-7	14936-14938	31	_
99-8	14939-14940	%	_
99-9	14941-14944	for	_
99-10	14945-14950	DLPFC	_
99-11	14951-14954	and	_
99-12	14955-14957	of	_
99-13	14958-14960	21	_
99-14	14961-14962	%	_
99-15	14963-14966	for	_
99-16	14967-14970	the	_
99-17	14971-14974	STR	_
99-18	14975-14976	.	_

100-1	14977-14981	More	_
100-2	14982-14989	details	_
100-3	14990-14999	regarding	_
100-4	15000-15009	selection	_
100-5	15010-15012	of	_
100-6	15013-15019	priors	_
100-7	15020-15023	are	_
100-8	15024-15032	provided	_
100-9	15033-15035	in	_
100-10	15036-15049	Supplementary	_
100-11	15050-15059	Materials	_
100-12	15060-15061	1	_
100-13	15062-15063	.	_

101-1	15064-15066	We	_
101-2	15067-15071	also	_
101-3	15072-15078	tested	_
101-4	15079-15086	whether	_
101-5	15087-15092	other	_
101-6	15093-15100	factors	_
101-7	15101-15110	differing	_
101-8	15111-15118	between	_
101-9	15119-15131	measurements	_
101-10	15132-15137	might	_
101-11	15138-15142	have	_
101-12	15143-15144	a	_
101-13	15145-15156	substantial	_
101-14	15157-15163	impact	_
101-15	15164-15166	on	_
101-16	15167-15170	the	_
101-17	15171-15178	results	_
101-18	15179-15182	and	_
101-19	15183-15190	thereby	_
101-20	15191-15194	act	_
101-21	15195-15197	as	_
101-22	15198-15199	a	_
101-23	15200-15210	confounder	_
101-24	15211-15212	.	_

102-1	15213-15218	These	_
102-2	15219-15226	factors	_
102-3	15227-15233	relate	_
102-4	15234-15236	to	_
102-5	15237-15240	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
102-6	15241-15252	acquisition	_
102-7	15253-15254	(	_
102-8	15255-15257	2D	_
102-9	15258-15260	or	_
102-10	15261-15263	3D	_
102-11	15264-15267	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
102-12	15268-15279	acquisition	_
102-13	15280-15281	,	_
102-14	15282-15290	presence	_
102-15	15291-15293	of	_
102-16	15294-15301	absence	_
102-17	15302-15304	of	_
102-18	15305-15308	the	_
102-19	15309-15320	Neuroinsert	_
102-20	15321-15322	,	_
102-21	15323-15334	measurement	_
102-22	15335-15341	length	_
102-23	15342-15343	,	_
102-24	15344-15348	date	_
102-25	15349-15351	of	_
102-26	15352-15363	measurement	_
102-27	15364-15365	,	_
102-28	15366-15370	i.e.	_
102-29	15371-15372	,	_
102-30	15373-15378	drift	_
102-31	15379-15383	over	_
102-32	15384-15388	time	_
102-33	15389-15390	)	_
102-34	15391-15392	,	_
102-35	15393-15396	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
102-36	15397-15411	reconstruction	_
102-37	15412-15413	(	_
102-38	15414-15417	R-Z	_
102-39	15418-15424	filter	_
102-40	15425-15435	resolution	_
102-41	15436-15437	,	_
102-42	15438-15441	R-Z	_
102-43	15442-15448	filter	_
102-44	15449-15455	cutoff	_
102-45	15456-15457	)	_
102-46	15458-15459	,	_
102-47	15460-15463	ROI	_
102-48	15464-15475	delineation	_
102-49	15476-15477	(	_
102-50	15478-15489	unconscious	_
102-51	15490-15496	biases	_
102-52	15497-15503	during	_
102-53	15504-15515	delineation	_
102-54	15516-15517	,	_
102-55	15518-15528	anatomical	_
102-56	15529-15531	MR	_
102-57	15532-15537	image	_
102-58	15538-15546	modality	_
102-59	15547-15548	-	_
102-60	15549-15552	T1w	_
102-61	15553-15555	vs	_
102-62	15556-15559	T2w	_
102-63	15560-15561	)	_
102-64	15562-15563	,	_
102-65	15564-15568	data	_
102-66	15569-15580	conversions	_
102-67	15581-15582	(	_
102-68	15583-15588	ecat6	_
102-69	15589-15591	or	_
102-70	15592-15597	ecat7	_
102-71	15598-15600	as	_
102-72	15601-15604	the	_
102-73	15605-15613	original	_
102-74	15614-15618	file	_
102-75	15619-15625	format	_
102-76	15626-15627	)	_
102-77	15628-15629	,	_
102-78	15630-15633	and	_
102-79	15634-15645	participant	_
102-80	15646-15653	factors	_
102-81	15654-15655	(	_
102-82	15656-15659	sex	_
102-83	15660-15663	and	_
102-84	15664-15672	movement	_
102-85	15673-15674	)	_
102-86	15675-15676	.	_

103-1	15677-15680	For	_
103-2	15681-15684	the	_
103-3	15685-15695	assessment	_
103-4	15696-15698	of	_
103-5	15699-15706	whether	_
103-6	15707-15711	BPND	_
103-7	15712-15715	was	_
103-8	15716-15724	affected	_
103-9	15725-15727	by	_
103-10	15728-15739	participant	_
103-11	15740-15743	sex	_
103-12	15744-15745	,	_
103-13	15746-15748	we	_
103-14	15749-15753	also	_
103-15	15754-15758	made	_
103-16	15759-15762	use	_
103-17	15763-15765	of	_
103-18	15766-15769	the	_
103-19	15770-15777	outcome	_
103-20	15778-15782	data	_
103-21	15783-15787	from	_
103-22	15788-15790	de	_
103-23	15791-15795	Boer	_
103-24	15796-15798	et	_
103-25	15799-15801	al	_
103-26	15802-15803	,	_
103-27	15804-15808	with	_
103-28	15809-15815	gender	_
103-29	15816-15824	provided	_
103-30	15825-15832	through	_
103-31	15833-15841	personal	_
103-32	15842-15855	communication	_
103-33	15856-15857	,	_
103-34	15858-15860	as	_
103-35	15861-15865	well	_
103-36	15866-15868	as	_
103-37	15869-15872	the	_
103-38	15873-15876	raw	_
103-39	15877-15881	data	_
103-40	15882-15890	utilized	_
103-41	15891-15893	in	_
103-42	15894-15901	Bäckman	_
103-43	15902-15904	et	_
103-44	15905-15907	al	_
103-45	15908-15909	.	_

104-1	15910-15913	but	_
104-2	15914-15918	with	_
104-3	15919-15924	image	_
104-4	15925-15933	analysis	_
104-5	15934-15937	and	_
104-6	15938-15947	modelling	_
104-7	15948-15957	performed	_
104-8	15958-15960	in	_
104-9	15961-15962	a	_
104-10	15963-15969	manner	_
104-11	15970-15979	identical	_
104-12	15980-15982	to	_
104-13	15983-15986	the	_
104-14	15987-15994	present	_
104-15	15995-16000	study	_
104-16	16001-16002	.	_

105-1	16003-16005	To	_
105-2	16006-16012	assess	_
105-3	16013-16020	whether	_
105-4	16021-16026	these	_
105-5	16027-16034	factors	_
105-6	16035-16043	impacted	_
105-7	16044-16047	our	_
105-8	16048-16056	outcomes	_
105-9	16057-16058	,	_
105-10	16059-16061	we	_
105-11	16062-16068	tested	_
105-12	16069-16076	whether	_
105-13	16077-16078	a	_
105-14	16079-16084	large	_
105-15	16085-16093	specific	_
105-16	16094-16100	effect	_
105-17	16101-16104	was	_
105-18	16105-16111	absent	_
105-19	16112-16115	for	_
105-20	16116-16120	each	_
105-21	16121-16127	factor	_
105-22	16128-16129	.	_

106-1	16130-16134	Such	_
106-2	16135-16146	conclusions	_
106-3	16147-16150	can	_
106-4	16151-16154	not	_
106-5	16155-16157	be	_
106-6	16158-16163	drawn	_
106-7	16164-16168	from	_
106-8	16169-16171	an	_
106-9	16172-16185	insignificant	_
106-10	16186-16187	P	_
106-11	16188-16193	value	_
106-12	16194-16203	assessing	_
106-13	16204-16207	the	_
106-14	16208-16219	differences	_
106-15	16220-16227	between	_
106-16	16228-16234	groups	_
106-17	16235-16238	but	_
106-18	16239-16245	rather	_
106-19	16246-16254	requires	_
106-20	16255-16256	a	_
106-21	16257-16261	test	_
106-22	16262-16264	of	_
106-23	16265-16271	groups	_
106-24	16272-16273	’	_
106-25	16274-16284	similarity	_
106-26	16285-16286	.	_

107-1	16287-16290	For	_
107-2	16291-16295	this	_
107-3	16296-16302	reason	_
107-4	16303-16304	,	_
107-5	16305-16307	we	_
107-6	16308-16312	made	_
107-7	16313-16316	use	_
107-8	16317-16319	of	_
107-9	16320-16331	equivalence	_
107-10	16332-16339	testing	_
107-11	16340-16341	.	_

108-1	16342-16346	This	_
108-2	16347-16353	allows	_
108-3	16354-16357	for	_
108-4	16358-16365	testing	_
108-5	16366-16368	of	_
108-6	16369-16372	the	_
108-7	16373-16384	equivalence	_
108-8	16385-16387	of	_
108-9	16388-16396	outcomes	_
108-10	16397-16398	,	_
108-11	16399-16405	rather	_
108-12	16406-16410	than	_
108-13	16411-16414	the	_
108-14	16415-16425	difference	_
108-15	16426-16427	,	_
108-16	16428-16431	and	_
108-17	16432-16440	requires	_
108-18	16441-16444	the	_
108-19	16445-16456	description	_
108-20	16457-16459	of	_
108-21	16460-16471	appropriate	_
108-22	16472-16483	equivalence	_
108-23	16484-16490	bounds	_
108-24	16491-16497	within	_
108-25	16498-16503	which	_
108-26	16504-16507	the	_
108-27	16508-16516	outcomes	_
108-28	16517-16520	are	_
108-29	16521-16528	assumed	_
108-30	16529-16531	to	_
108-31	16532-16534	be	_
108-32	16535-16547	sufficiently	_
108-33	16548-16555	similar	_
108-34	16556-16557	.	_

109-1	16558-16560	We	_
109-2	16561-16570	performed	_
109-3	16571-16572	a	_
109-4	16573-16578	power	_
109-5	16579-16587	analysis	_
109-6	16588-16591	for	_
109-7	16592-16595	the	_
109-8	16596-16607	equivalence	_
109-9	16608-16613	bound	_
109-10	16614-16617	for	_
109-11	16618-16626	2-sample	_
109-12	16627-16638	equivalence	_
109-13	16639-16644	tests	_
109-14	16645-16649	with	_
109-15	16650-16651	a	_
109-16	16652-16656	type	_
109-17	16657-16658	I	_
109-18	16659-16664	error	_
109-19	16665-16669	rate	_
109-20	16670-16672	of	_
109-21	16673-16677	0.05	_
109-22	16678-16679	,	_
109-23	16680-16681	a	_
109-24	16682-16687	power	_
109-25	16688-16690	of	_
109-26	16691-16694	0.8	_
109-27	16695-16696	,	_
109-28	16697-16700	and	_
109-29	16701-16708	samples	_
109-30	16709-16711	of	_
109-31	16712-16714	18	_
109-32	16715-16717	in	_
109-33	16718-16722	each	_
109-34	16723-16728	group	_
109-35	16729-16730	.	_

110-1	16731-16740	According	_
110-2	16741-16743	to	_
110-3	16744-16748	this	_
110-4	16749-16757	analysis	_
110-5	16758-16759	,	_
110-6	16760-16765	there	_
110-7	16766-16769	was	_
110-8	16770-16780	sufficient	_
110-9	16781-16786	power	_
110-10	16787-16789	to	_
110-11	16790-16796	assess	_
110-12	16797-16808	equivalence	_
110-13	16809-16815	within	_
110-14	16816-16822	bounds	_
110-15	16823-16825	of	_
110-16	16826-16828	−1	_
110-17	16829-16830	<	_
110-18	16831-16836	Cohen	_
110-19	16837-16838	’	_
110-20	16839-16840	s	_
110-21	16841-16842	D	_
110-22	16843-16844	<	_
110-23	16845-16846	1	_
110-24	16847-16848	.	_

111-1	16849-16854	Since	_
111-2	16855-16860	Cohen	_
111-3	16861-16862	’	_
111-4	16863-16864	s	_
111-5	16865-16866	D	_
111-6	16867-16868	=	_
111-7	16869-16872	0.8	_
111-8	16873-16883	represents	_
111-9	16884-16885	a	_
111-10	16886-16891	large	_
111-11	16892-16898	effect	_
111-12	16899-16903	size	_
111-13	16904-16905	,	_
111-14	16906-16908	we	_
111-15	16909-16912	can	_
111-16	16913-16920	thereby	_
111-17	16921-16925	rule	_
111-18	16926-16929	out	_
111-19	16930-16935	large	_
111-20	16936-16943	effects	_
111-21	16944-16945	.	_

112-1	16946-16951	While	_
112-2	16952-16954	it	_
112-3	16955-16960	would	_
112-4	16961-16965	have	_
112-5	16966-16970	been	_
112-6	16971-16980	desirable	_
112-7	16981-16983	to	_
112-8	16984-16990	assess	_
112-9	16991-17002	equivalence	_
112-10	17003-17009	within	_
112-11	17010-17014	more	_
112-12	17015-17026	restrictive	_
112-13	17027-17038	equivalence	_
112-14	17039-17045	bounds	_
112-15	17046-17047	,	_
112-16	17048-17052	this	_
112-17	17053-17061	approach	_
112-18	17062-17064	is	_
112-19	17065-17076	nonetheless	_
112-20	17077-17085	superior	_
112-21	17086-17088	to	_
112-22	17089-17092	the	_
112-23	17093-17106	statistically	_
112-24	17107-17114	invalid	_
112-25	17115-17123	approach	_
112-26	17124-17126	of	_
112-27	17127-17136	accepting	_
112-28	17137-17138	(	_
112-29	17139-17141	as	_
112-30	17142-17149	opposed	_
112-31	17150-17152	to	_
112-32	17153-17160	failing	_
112-33	17161-17163	to	_
112-34	17164-17170	reject	_
112-35	17171-17172	)	_
112-36	17173-17176	the	_
112-37	17177-17181	null	_
112-38	17182-17192	hypothesis	_
112-39	17193-17198	based	_
112-40	17199-17201	on	_
112-41	17202-17203	a	_
112-42	17204-17218	nonsignificant	_
112-43	17219-17220	P	_
112-44	17221-17226	value	_
112-45	17227-17229	in	_
112-46	17230-17231	a	_
112-47	17232-17236	test	_
112-48	17237-17246	assessing	_
112-49	17247-17258	differences	_
112-50	17259-17260	.	_

113-1	17261-17273	Transparency	_
113-2	17274-17283	Statement	_
113-3	17284-17286	We	_
113-4	17287-17294	present	_
113-5	17295-17298	the	_
113-6	17299-17308	following	_
113-7	17309-17321	transparency	_
113-8	17322-17331	statement	_
113-9	17332-17341	suggested	_
113-10	17342-17344	by	_
113-11	17345-17352	Simmons	_
113-12	17353-17355	et	_
113-13	17356-17358	al	_
113-14	17359-17361	..	_
113-15	17362-17365	All	_
113-16	17366-17378	requirements	_
113-17	17379-17382	are	_
113-18	17383-17392	presented	_
113-19	17393-17398	below	_
113-20	17399-17400	.	_

114-1	17401-17403	We	_
114-2	17404-17410	report	_
114-3	17411-17414	how	_
114-4	17415-17417	we	_
114-5	17418-17428	determined	_
114-6	17429-17432	our	_
114-7	17433-17439	sample	_
114-8	17440-17444	size	_
114-9	17445-17446	,	_
114-10	17447-17450	all	_
114-11	17451-17455	data	_
114-12	17456-17466	exclusions	_
114-13	17467-17468	(	_
114-14	17469-17471	if	_
114-15	17472-17475	any	_
114-16	17476-17477	)	_
114-17	17478-17479	,	_
114-18	17480-17483	all	_
114-19	17484-17497	manipulations	_
114-20	17498-17499	,	_
114-21	17500-17503	and	_
114-22	17504-17507	all	_
114-23	17508-17516	measures	_
114-24	17517-17519	in	_
114-25	17520-17523	the	_
114-26	17524-17529	study	_
114-27	17530-17531	.	_

115-1	17532-17538	Sample	_
115-2	17539-17543	Size	_
115-3	17544-17557	Determination	_
115-4	17558-17561	The	_
115-5	17562-17567	final	_
115-6	17568-17573	study	_
115-7	17574-17580	sample	_
115-8	17581-17585	size	_
115-9	17586-17589	was	_
115-10	17590-17600	determined	_
115-11	17601-17603	by	_
115-12	17604-17607	the	_
115-13	17608-17614	number	_
115-14	17615-17617	of	_
115-15	17618-17630	participants	_
115-16	17631-17639	included	_
115-17	17640-17642	in	_
115-18	17643-17646	the	_
115-19	17647-17652	study	_
115-20	17653-17657	when	_
115-21	17658-17660	it	_
115-22	17661-17664	was	_
115-23	17665-17672	decided	_
115-24	17673-17677	that	_
115-25	17678-17682	data	_
115-26	17683-17693	collection	_
115-27	17694-17697	was	_
115-28	17698-17700	to	_
115-29	17701-17703	be	_
115-30	17704-17713	concluded	_
115-31	17714-17716	in	_
115-32	17717-17721	2008	_
115-33	17722-17725	and	_
115-34	17726-17735	consisted	_
115-35	17736-17738	of	_
115-36	17739-17741	18	_
115-37	17742-17750	patients	_
115-38	17751-17754	and	_
115-39	17755-17757	18	_
115-40	17758-17765	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
115-41	17766-17774	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
115-42	17775-17776	.	_

116-1	17777-17779	No	_
116-2	17780-17785	power	_
116-3	17786-17794	analysis	_
116-4	17795-17798	was	_
116-5	17799-17808	performed	_
116-6	17809-17815	before	_
116-7	17816-17818	or	_
116-8	17819-17825	during	_
116-9	17826-17829	the	_
116-10	17830-17835	study	_
116-11	17836-17837	;	_
116-12	17838-17845	however	_
116-13	17846-17847	,	_
116-14	17848-17849	a	_
116-15	17850-17855	power	_
116-16	17856-17864	analysis	_
116-17	17865-17868	was	_
116-18	17869-17878	performed	_
116-19	17879-17884	prior	_
116-20	17885-17887	to	_
116-21	17888-17899	statistical	_
116-22	17900-17908	analysis	_
116-23	17909-17910	.	_

117-1	17911-17914	For	_
117-2	17915-17916	a	_
117-3	17917-17918	2	_
117-4	17919-17930	independent	_
117-5	17931-17937	sample	_
117-6	17938-17939	t	_
117-7	17940-17944	test	_
117-8	17945-17946	,	_
117-9	17947-17951	with	_
117-10	17952-17954	an	_
117-11	17955-17960	alpha	_
117-12	17961-17963	of	_
117-13	17964-17968	0.05	_
117-14	17969-17970	,	_
117-15	17971-17975	this	_
117-16	17976-17981	study	_
117-17	17982-17985	had	_
117-18	17986-17988	80	_
117-19	17989-17990	%	_
117-20	17991-17996	power	_
117-21	17997-17999	to	_
117-22	18000-18006	detect	_
117-23	18007-18009	an	_
117-24	18010-18016	effect	_
117-25	18017-18021	size	_
117-26	18022-18024	of	_
117-27	18025-18030	Cohen	_
117-28	18031-18032	’	_
117-29	18033-18034	s	_
117-30	18035-18036	D	_
117-31	18037-18038	=	_
117-32	18039-18043	0.96	_
117-33	18044-18045	.	_

118-1	18046-18050	This	_
118-2	18051-18062	corresponds	_
118-3	18063-18065	to	_
118-4	18066-18067	a	_
118-5	18068-18073	Cohen	_
118-6	18074-18075	’	_
118-7	18076-18077	s	_
118-8	18078-18080	U3	_
118-9	18081-18083	of	_
118-10	18084-18086	83	_
118-11	18087-18088	%	_
118-12	18089-18092	and	_
118-13	18093-18094	a	_
118-14	18095-18101	common	_
118-15	18102-18110	language	_
118-16	18111-18117	effect	_
118-17	18118-18122	size	_
118-18	18123-18125	of	_
118-19	18126-18128	75	_
118-20	18129-18130	%	_
118-21	18131-18132	.	_

119-1	18133-18137	This	_
119-2	18138-18144	effect	_
119-3	18145-18147	is	_
119-4	18148-18154	larger	_
119-5	18155-18159	than	_
119-6	18160-18162	we	_
119-7	18163-18168	would	_
119-8	18169-18175	expect	_
119-9	18176-18177	,	_
119-10	18178-18181	and	_
119-11	18182-18184	we	_
119-12	18185-18195	determined	_
119-13	18196-18197	a	_
119-14	18198-18204	priori	_
119-15	18205-18209	that	_
119-16	18210-18212	if	_
119-17	18213-18224	significant	_
119-18	18225-18226	,	_
119-19	18227-18231	this	_
119-20	18232-18238	result	_
119-21	18239-18244	could	_
119-22	18245-18251	likely	_
119-23	18252-18261	represent	_
119-24	18262-18263	a	_
119-25	18264-18268	Type	_
119-26	18269-18270	M	_
119-27	18271-18276	error	_
119-28	18277-18278	,	_
119-29	18279-18282	and	_
119-30	18283-18285	if	_
119-31	18286-18299	insignificant	_
119-32	18300-18301	,	_
119-33	18302-18306	this	_
119-34	18307-18313	result	_
119-35	18314-18319	could	_
119-36	18320-18326	likely	_
119-37	18327-18336	represent	_
119-38	18337-18338	a	_
119-39	18339-18343	Type	_
119-40	18344-18346	II	_
119-41	18347-18352	error	_
119-42	18353-18354	.	_

120-1	18355-18365	Exclusions	_
120-2	18366-18369	One	_
120-3	18370-18373	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
120-4	18374-18385	measurement	_
120-5	18386-18390	from	_
120-6	18391-18392	a	_
120-7	18393-18400	control	_
120-8	18401-18408	subject	_
120-9	18409-18412	was	_
120-10	18413-18421	excluded	_
120-11	18422-18426	from	_
120-12	18427-18430	the	_
120-13	18431-18439	analysis	_
120-14	18440-18445	since	_
120-15	18446-18448	it	_
120-16	18449-18452	was	_
120-17	18453-18457	only	_
120-18	18458-18464	stored	_
120-19	18465-18467	on	_
120-20	18468-18470	an	_
120-21	18471-18478	optical	_
120-22	18479-18483	disc	_
120-23	18484-18489	whose	_
120-24	18490-18497	content	_
120-25	18498-18503	could	_
120-26	18504-18507	not	_
120-27	18508-18510	be	_
120-28	18511-18519	accessed	_
120-29	18520-18521	.	_

121-1	18522-18525	All	_
121-2	18526-18531	other	_
121-3	18532-18544	measurements	_
121-4	18545-18549	were	_
121-5	18550-18558	included	_
121-6	18559-18561	in	_
121-7	18562-18565	the	_
121-8	18566-18574	analysis	_
121-9	18575-18576	.	_

122-1	18577-18585	Measures	_
122-2	18586-18589	and	_
122-3	18590-18598	Analyses	_
122-4	18599-18602	The	_
122-5	18603-18610	authors	_
122-6	18611-18618	confirm	_
122-7	18619-18623	that	_
122-8	18624-18627	all	_
122-9	18628-18631	ROI	_
122-10	18632-18643	delineation	_
122-11	18644-18647	was	_
122-12	18648-18657	performed	_
122-13	18658-18663	blind	_
122-14	18664-18666	to	_
122-15	18667-18670	the	_
122-16	18671-18678	patient	_
122-17	18679-18681	or	_
122-18	18682-18689	control	_
122-19	18690-18696	status	_
122-20	18697-18699	of	_
122-21	18700-18703	the	_
122-22	18704-18712	subjects	_
122-23	18713-18716	and	_
122-24	18717-18721	that	_
122-25	18722-18724	no	_
122-26	18725-18732	regions	_
122-27	18733-18738	other	_
122-28	18739-18743	than	_
122-29	18744-18747	the	_
122-30	18748-18753	whole	_
122-31	18754-18757	STR	_
122-32	18758-18761	and	_
122-33	18762-18765	the	_
122-34	18766-18771	DLPFC	_
122-35	18772-18776	were	_
122-36	18777-18785	analyzed	_
122-37	18786-18787	.	_

123-1	18788-18791	All	_
123-2	18792-18802	confounder	_
123-3	18803-18809	checks	_
123-4	18810-18814	were	_
123-5	18815-18823	analyzed	_
123-6	18824-18831	without	_
123-7	18832-18839	testing	_
123-8	18840-18847	whether	_
123-9	18848-18852	they	_
123-10	18853-18863	influenced	_
123-11	18864-18867	the	_
123-12	18868-18873	final	_
123-13	18874-18881	outcome	_
123-14	18882-18883	,	_
123-15	18884-18887	and	_
123-16	18888-18903	patient-control	_
123-17	18904-18910	status	_
123-18	18911-18914	was	_
123-19	18915-18918	not	_
123-20	18919-18927	included	_
123-21	18928-18930	in	_
123-22	18931-18934	any	_
123-23	18935-18943	analysis	_
123-24	18944-18949	other	_
123-25	18950-18954	than	_
123-26	18955-18959	that	_
123-27	18960-18962	of	_
123-28	18963-18966	ROI	_
123-29	18967-18978	delineation	_
123-30	18979-18983	bias	_
123-31	18984-18985	,	_
123-32	18986-18991	where	_
123-33	18992-18994	it	_
123-34	18995-18998	was	_
123-35	18999-19002	the	_
123-36	19003-19014	independent	_
123-37	19015-19023	variable	_
123-38	19024-19025	.	_

124-1	19026-19029	For	_
124-2	19030-19042	transparency	_
124-3	19043-19044	,	_
124-4	19045-19047	we	_
124-5	19048-19052	note	_
124-6	19053-19057	that	_
124-7	19058-19060	an	_
124-8	19061-19072	exploratory	_
124-9	19073-19076	SPM	_
124-10	19077-19085	analysis	_
124-11	19086-19089	was	_
124-12	19090-19093	run	_
124-13	19094-19096	on	_
124-14	19097-19098	a	_
124-15	19099-19105	subset	_
124-16	19106-19108	of	_
124-17	19109-19117	subjects	_
124-18	19118-19124	during	_
124-19	19125-19128	the	_
124-20	19129-19133	data	_
124-21	19134-19144	collection	_
124-22	19145-19150	phase	_
124-23	19151-19154	for	_
124-24	19155-19160	which	_
124-25	19161-19166	there	_
124-26	19167-19171	were	_
124-27	19172-19174	no	_
124-28	19175-19186	significant	_
124-29	19187-19198	differences	_
124-30	19199-19206	between	_
124-31	19207-19210	the	_
124-32	19211-19217	groups	_
124-33	19218-19223	using	_
124-34	19224-19236	conventional	_
124-35	19237-19248	statistical	_
124-36	19249-19259	thresholds	_
124-37	19260-19261	.	_

125-1	19262-19267	Hence	_
125-2	19268-19269	,	_
125-3	19270-19275	there	_
125-4	19276-19280	were	_
125-5	19281-19283	no	_
125-6	19284-19295	significant	_
125-7	19296-19304	findings	_
125-8	19305-19312	guiding	_
125-9	19313-19316	the	_
125-10	19317-19320	ROI	_
125-11	19321-19329	analysis	_
125-12	19330-19331	.	_

126-1	19332-19339	However	_
126-2	19340-19341	,	_
126-3	19342-19345	due	_
126-4	19346-19348	to	_
126-5	19349-19352	the	_
126-6	19353-19364	differences	_
126-7	19365-19367	in	_
126-8	19368-19370	MR	_
126-9	19371-19379	modality	_
126-10	19380-19381	,	_
126-11	19382-19385	the	_
126-12	19386-19390	fact	_
126-13	19391-19395	that	_
126-14	19396-19400	this	_
126-15	19401-19409	analysis	_
126-16	19410-19413	was	_
126-17	19414-19417	not	_
126-18	19418-19427	corrected	_
126-19	19428-19431	for	_
126-20	19432-19441	different	_
126-21	19442-19449	lengths	_
126-22	19450-19452	of	_
126-23	19453-19464	measurement	_
126-24	19465-19467	as	_
126-25	19468-19472	well	_
126-26	19473-19475	as	_
126-27	19476-19479	the	_
126-28	19480-19484	poor	_
126-29	19485-19496	reliability	_
126-30	19497-19499	of	_
126-31	19500-19509	voxelwise	_
126-32	19510-19519	estimates	_
126-33	19520-19522	of	_
126-34	19523-19531	cortical	_
126-35	19532-19533	[	_
126-36	19534-19537	11C	_
126-37	19538-19539	]	_
126-38	19540-19548	SCH23390	_
126-39	19549-19553	BPND	_
126-40	19554-19555	,	_
126-41	19556-19558	we	_
126-42	19559-19561	do	_
126-43	19562-19565	not	_
126-44	19566-19574	consider	_
126-45	19575-19580	these	_
126-46	19581-19588	results	_
126-47	19589-19591	to	_
126-48	19592-19594	be	_
126-49	19595-19600	valid	_
126-50	19601-19602	,	_
126-51	19603-19606	and	_
126-52	19607-19611	this	_
126-53	19612-19614	is	_
126-54	19615-19623	reported	_
126-55	19624-19630	solely	_
126-56	19631-19634	for	_
126-57	19635-19638	the	_
126-58	19639-19646	purpose	_
126-59	19647-19649	of	_
126-60	19650-19662	transparency	_
126-61	19663-19664	.	_

127-1	19665-19667	In	_
127-2	19668-19671	the	_
127-3	19672-19679	current	_
127-4	19680-19688	analysis	_
127-5	19689-19690	,	_
127-6	19691-19693	we	_
127-7	19694-19704	restricted	_
127-8	19705-19708	the	_
127-9	19709-19710	a	_
127-10	19711-19717	priori	_
127-11	19718-19722	ROIs	_
127-12	19723-19725	to	_
127-13	19726-19729	the	_
127-14	19730-19735	DLPFC	_
127-15	19736-19739	and	_
127-16	19740-19743	STR	_
127-17	19744-19745	,	_
127-18	19746-19748	as	_
127-19	19749-19751	we	_
127-20	19752-19756	have	_
127-21	19757-19759	in	_
127-22	19760-19768	previous	_
127-23	19769-19776	studies	_
127-24	19777-19778	(	_
127-25	19779-19782	REF	_
127-26	19783-19787	here	_
127-27	19788-19789	:	_
127-28	19790-19795	https	_
127-29	19796-19797	:	_
127-30	19798-19840	//www.biorxiv.org/content/10.1101/321646v2	_
127-31	19841-19842	)	_
127-32	19843-19845	to	_
127-33	19846-19852	reduce	_
127-34	19853-19856	the	_
127-35	19857-19866	potential	_
127-36	19867-19876	influence	_
127-37	19877-19879	of	_
127-38	19880-19888	multiple	_
127-39	19889-19900	comparisons	_
127-40	19901-19903	to	_
127-41	19904-19908	test	_
127-42	19909-19912	the	_
127-43	19913-19916	D1R	_
127-44	19917-19927	hypothesis	_
127-45	19928-19929	.	_

128-1	19930-19934	Data	_
128-2	19935-19938	and	_
128-3	19939-19943	Code	_
128-4	19944-19956	Availability	_
128-5	19957-19960	All	_
128-6	19961-19969	analysis	_
128-7	19970-19974	code	_
128-8	19975-19977	is	_
128-9	19978-19987	available	_
128-10	19988-19990	at	_
128-11	19991-19996	https	_
128-12	19997-19998	:	_
128-13	19999-20035	//github.com/mathesong/D1DNPsychosis	_
128-14	20036-20037	.	_

129-1	20038-20041	Due	_
129-2	20042-20044	to	_
129-3	20045-20058	institutional	_
129-4	20059-20071	restrictions	_
129-5	20072-20073	,	_
129-6	20074-20077	the	_
129-7	20078-20082	data	_
129-8	20083-20086	can	_
129-9	20087-20090	not	_
129-10	20091-20093	be	_
129-11	20094-20100	shared	_
129-12	20101-20107	openly	_
129-13	20108-20114	within	_
129-14	20115-20119	this	_
129-15	20120-20130	repository	_
129-16	20131-20132	.	_

130-1	20133-20138	These	_
130-2	20139-20143	data	_
130-3	20144-20147	are	_
130-4	20148-20161	pseudonymized	_
130-5	20162-20171	according	_
130-6	20172-20174	to	_
130-7	20175-20183	national	_
130-8	20184-20185	(	_
130-9	20186-20193	Swedish	_
130-10	20194-20195	)	_
130-11	20196-20199	and	_
130-12	20200-20202	EU	_
130-13	20203-20214	legislation	_
130-14	20215-20218	and	_
130-15	20219-20222	can	_
130-16	20223-20226	not	_
130-17	20227-20229	be	_
130-18	20230-20240	anonymized	_
130-19	20241-20244	and	_
130-20	20245-20254	published	_
130-21	20255-20257	in	_
130-22	20258-20260	an	_
130-23	20261-20265	open	_
130-24	20266-20276	repository	_
130-25	20277-20278	.	_

131-1	20279-20287	Metadata	_
131-2	20288-20291	can	_
131-3	20292-20294	be	_
131-4	20295-20301	openly	_
131-5	20302-20311	published	_
131-6	20312-20313	,	_
131-7	20314-20317	and	_
131-8	20318-20321	the	_
131-9	20322-20332	underlying	_
131-10	20333-20337	data	_
131-11	20338-20341	can	_
131-12	20342-20349	instead	_
131-13	20350-20352	be	_
131-14	20353-20357	made	_
131-15	20358-20367	available	_
131-16	20368-20372	upon	_
131-17	20373-20380	request	_
131-18	20381-20383	on	_
131-19	20384-20385	a	_
131-20	20386-20390	case	_
131-21	20391-20393	by	_
131-22	20394-20398	case	_
131-23	20399-20404	basis	_
131-24	20405-20407	as	_
131-25	20408-20415	allowed	_
131-26	20416-20418	by	_
131-27	20419-20422	the	_
131-28	20423-20434	legislation	_
131-29	20435-20438	and	_
131-30	20439-20446	ethical	_
131-31	20447-20454	permits	_
131-32	20455-20456	.	_

132-1	20457-20465	Requests	_
132-2	20466-20469	for	_
132-3	20470-20476	access	_
132-4	20477-20480	can	_
132-5	20481-20483	be	_
132-6	20484-20488	made	_
132-7	20489-20491	to	_
132-8	20492-20495	the	_
132-9	20496-20506	Karolinska	_
132-10	20507-20517	Institutet	_
132-11	20518-20519	’	_
132-12	20520-20521	s	_
132-13	20522-20530	Research	_
132-14	20531-20535	Data	_
132-15	20536-20542	Office	_
132-16	20543-20545	at	_
132-17	20546-20549	rdo	_
132-18	20550-20551	@	_
132-19	20552-20557	ki.se	_
132-20	20558-20559	.	_

